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STUDY OF IRON OXIDE MAGNETIC NANOPARTICLES IN CANCER CELL 
DESTRUCTION AND CELL SEPARATION 
Jiaqi Zhao, PhD 
University of Pittsburgh, 2018 
Due to their adjustable physiochemical properties and proven biocompatibility, iron oxide 
(Fe3O4) magnetic nanoparticles are promising in drug delivery, magnetic resonance imaging and 
catalysis. In this thesis, we have utilized two types of iron oxide nanoparticles: i) 
superparamagnetic iron oxide nanoparticles (SPION) for targeted destruction of cancer cells, and 
ii) poly(N-isopropylacrylamide) (pNIPAM) coated magnetic particles (MNP) for multistage cell 
separation. 
SPION are generally considered as drug delivery vehicles for the enhanced permeability 
and retention (EPR) effect. SPION possess the intrinsic peroxidase-like activity as Horseradish 
peroxidase (HRP), which can generate reactive oxygen species (ROS) from H2O2 via Fenton’s 
reaction. ROS regulate cell signaling, but a significant ROS stress can disrupt the redox 
homeostasis of cancer cells leading to selective tumor cell toxicity and destruction. Hereby, we 
developed ROS-induced targeted cell destruction with SPION-GOx bioconjugates platform. 
GOx catalyzes glucose oxidation in cancer cells to produce H2O2. 24 h incubation with 10 μg/mL 
SPION-GOx on 4T1 cells resulted in almost zero cell viability. In vivo evaluation showed 
SPION-GOx led to a much slower tumor growth compared to control groups. 
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Additionally, magnetic activated cell sorting (MACS) has become a common technique 
for the separation of target cell populations from biological suspensions. A major obstacle 
preventing current single stage MACS from achieving satisfying separation efficiency is the non-
specific interactions between the cells and MNP. Thus, we designed a multistage separation 
platform similar to distillation concept in chemical engineering. The repeated capture-and-
release separation process is enabled by attaching the temperature responsive polymer- pNIPAM 
to both MNP and target cells. We manipulate the reversible hydrophobic-hydrophilic interactions 
between such functionalized MNP and target cells through temperature cycling to capture and 
release target cells at a higher efficiency than non-target. After several temperature cycles, target 
cells are enriched in the product. Flow cytometry results suggest that A431 cells (target) could be 
effectively separated from HeLa cells (non-target) after three separation stages resulting in an 
enrichment factor of 3.69 when the starting ratio of target to non-target is 1:2. 
 vi 
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1.0  INTRODUCTION 
This dissertation consists of two parts of work: 1) targeted destruction of cancer cells by glucose 
oxidase-iron oxide bioconjugates, and 2) multistage separation of cells using hydrophobic 
interactions enabled by temperature responsive polymers. Both projects utilized iron oxide 
(Fe3O4) magnetic nanoparticles for their adjustable physiochemical properties and proven 
biocompatibility. 
Fe3O4 magnetic nanoparticles are a promising candidate in varieties of biomedical 
applications such as drug delivery, cell sorting, magnetic resonance imaging (MRI) and catalysis. 
It is highly desirable to have the particles with controllable sizes so that they are comparable with 
different biological entities of interest. 
Superparamagnetic iron oxide nanoparticles (SPION) with sizes under 50 nm possess the 
same intrinsic peroxidase-like activity as Horseradish peroxidase (HRP). This property is widely 
used in wastewater treatment and detection tools.  SPION generate reactive oxygen species 
(ROS, which play an important role in cell signaling) from H2O2 via Fenton’s reaction. A 
significant oxidative stress from ROS can overwhelm the relatively low antioxidant capacity and 
disrupt the redox homeostasis of cancer cells, leading to selective tumor cell toxicity and 
destruction. Therefore, we developed a novel approach for ROS-induced targeted cell destruction 
with SPION-GOx bioconjugates. GOx stands for glucose oxidase, which is an enzyme that 
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catalyzes the oxidation of glucose to produce H2O2. Along with the enhanced permeability and 
retention (EPR) effect that enables SPION to accumulate passively in tumor, the synergetic 
effect of SPION-GOx provides a great opportunity to significantly reduce the side effects from 
the conventional ROS based chemotherapy and radiotherapy on normal tissues. This work is a 
novel cancer therapy strategy as a substitute or supplement treatment method of radiotherapy and 
photodynamic therapy (PDT). 
Additionally, magnetic activated cell sorting (MACS) has become a common technique 
for the separation of target cell populations from biological suspensions. A major obstacle 
preventing MACS from achieving satisfying separation efficiency is the non-specific interactions 
between the cells and MNP. Thus, we designed a multistage separation scheme by introducing 
multiple capture-and-release cycles to the separation process. By attaching pNIPAM to both 
MNP and target cells, we are able to manipulate the reversible hydrophobic-hydrophilic 
interactions between the functionalized MNP and target cells. This multistage separation 
approach is a promising MACS strategy in clinical prognosis and environment engineering, for 
example, detecting the rare circulating tumor cells (CTCs) from large volume blood samples and 
wastewater treatment. 
The following topics are discussed in this dissertation: synthesis, stabilization, unique 
properties, and applications of Fe3O4 magnetic nanoparticles; cancer treatment by reactive 
oxygen species (ROS); cancer prognosis by isolation and analysis circulating tumor cells 
(CTCs), targeted destruction of cancer cells by glucose oxidase-iron oxide bioconjugates and 
multistage separation of cells using hydrophobic interactions enabled by temperature responsive 
polymers. 
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1.1 IRON OXIDE MAGNETIC NANOPARTICLES: SYNTHESIS, STABILIZATION, 
PROPERTIES AND APPLICATIONS 
The research on nanoparticles has been growing so explosively in recent years that researchers 
are able to fabricate, characterize and functionalize particles for specific clinical purposes in a 
variety of biomedical applications including drug delivery, hyperthermia, MRI agent, separation 
and sorting biological organisms. Among several types of inorganic particles that have been 
investigated, the iron oxide (mostly Fe2O3 and Fe3O4) magnetic particle is a very promising 
candidate for its adjustable physical and chemical properties and proven biocompatibility. This 
provides great opportunity in site-specific drug delivery, hyperthermia treatment for malignant 
cells, magnetic resonance imaging contrast, cell labeling, targeting and as a tool for cell-biology 
research to separate and purify cell populations[1]. 
A major advantage of nanoparticles over bulk materials is the large surface area resulting 
in an improved reactivity[2]. It is necessary that the size and shape of the particles are 
controllable to be comparable with different biological entities of interest.  In order to meet the 
requirements for different situations, particles with diameters ranging from a few nanometers to 
hundreds of nanometers can be synthesized through several approaches, including physical 
methods such as gas phase deposition, electron beam lithography, and wet chemical routes like 
co-precipitation of Fe2+ and Fe3+ aqueous salt solutions by adding a base. In the meantime, the 
magnetic nanoparticles are usually required to be well dispersed in suitable solvents, especially 
aqueous solution for biomedical applications since agglomeration and/or precipitation may 
prevent nanoparticles from being delivered to a specific area[3]. Therefore, surface coating that 
stabilizes the magnetic particles is an important step after synthesis. In this dissertation, two 
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types of iron oxide nanoparticles were synthesized using two different approaches: 
superparamagnetic iron oxide nanoparticles (SPION) were prepared using thermal precipitation 
and were conjugated with glucose oxidase (GOx) for targeted destruction of cancer cells; 
poly(N-isopropylacrylamide) (pNIPAM) coated PAA-MNP via hydrothermal method for 
multistage cell separation. Some popular synthesis and stabilization methods are reviewed and 
compared in this section as well as special features of iron oxide nanoparticles and their 
biomedical applications. 
1.1.1 Synthesis 
During the past decades, synthesis methods for stable and monodisperse magnetic nanoparticles 
have been well studied. Co-precipitation, thermal decomposition, hydrothermal synthesis, and 
microemulsion are popular approaches for the synthesis of high-quality nanoparticles. 
Co-precipitation is a convenient way to synthesize iron oxides (Fe2O3 and Fe3O4) at 
temperature ranging from 20-90°C[1]. By adding a base to Fe2+/Fe3+ salt solution, magnetic 
nanoparticles can be prepared once the conditions are fixed, which include the type of salts used, 
Fe2+/Fe3+ ratio, reaction temperature, pH, and the ionic strength of the media. Particles 
synthesized by co-precipitation tend to have a wide size distribution, which is non-ideal for many 
applications. The well-known nucleation and growth theory indicates that the key to produce 
monodisperse nanoparticles from solution is the fast nucleation and the following slow 
controlled growth. Oleic acid is considered the best candidate as a surfactant to passivate the 
particle surface and produce uniform products in extensive studies on the effect of several 
organic ions, such as carboxylate and hydroxyl carboxylate ions, on stabilizing the magnetite, 
 5 
 
because spectroscopic characterizations showed that oleic acid ligand undergoes a structural 
change during γ-Fe2O3 nanocrystal synthesis[4]. The mechanism can be explained as the 
chelation of organic ions with metal ions reduces the number of nuclei, which leads to the 
particle growth step becoming dominant; in addition, the additives adhering to the nuclei and 
growing crystals may prevent the growth of particles, which favors the formation of small units 
[1]. 
Water-in-oil microemulsion (reverse micelles) can also be used as nanoreactor for the 
synthesis of magnetic nanoparticles. A microemulsion is thermodynamically stable dispersion 
with aqueous phase dispersed as microdroplets surrounded by a monolayer of surfactants in the 
continuous hydrocarbon phase. The resulting particles can be precipitated from the 
microemulsion by addition of acetone or ethanol, and subsequently extracted by centrifugal. 
Woo et al. reported Fe2O3 nanorods had been synthesized using the microemulsion method via a 
sol-gel-mediated route. The reverse micelles were formed from oleic acid and benzyl ether, with 
FeCl3•6H2O as the iron source and propylene oxide as the proton scavenger[5]. The limitations 
of the microemulsion technique are that the particle shape (e.g., spheroids or tubes) and size may 
vary over a wide range. Moreover, it is not an efficient process and usually gives a low yield 
compared to other methods[1]. 
In this study, according to the specific size and property requirements we set for the 
nanoparticles, thermal decomposition and hydrothermal synthesis were used to prepare the two 
types of iron oxide nanoparticles for targeted cancer cell destruction and magnetic assisted cell 
separation, respectively. Thus, a detailed discussion of these two synthesis methods, including 
reaction condition, mechanism and limitations, is given in the following section. 
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1.1.1.1 Thermal decomposition 
In order to produce highly uniform and small nanoparticles that can be used for cancer therapy 
study on animal models, the thermal decomposition method was taken to synthesize the ultra-
small superparamagnetic nanoparticles (SPION). Thermal decomposition of organometallic 
compounds in high boiling point solvent in the presence of stabilizing surfactants can yield 
monodisperse magnetic nanoparticles with very narrow size distribution. In this system, iron 
acetylacetonate, Fe(acac)3, is the organometallic precursor and oleic acid is used as the 
surfactant. Iron in Fe(III) oxides could be replaced by other metals such as Mn, Co, Ni, Cr[6]; 
fatty acids and hexadecylamine are alternative surfactants. The size and morphology are 
determined mainly by the ratios of the reagents (organometallic compounds, surfactant, and 
solvent), but also affected by reaction temperature, reaction time, and in some cases, the aging 
period[7]. Examples showing the effects of these decisive factors will be given below. 
Peng et al. reported a general and reproducible strategy using generic chemicals for 
controlling the size, shape, and the size distribution of magnetic oxide nanocrystals[8, 9]. Nearly 
monodisperse dot-shaped (as compared to tube- and wire-shaped) Fe3O4 nanocrystals were 
synthesized in the size range between about 6 and 50 nm, as shown in Figure 1. The method is 
based on the pyrolysis of metal fatty acid salts in nonaqueous solutions, which uses either 
octadecene (ODE), n-eicosane, tetracosane, or a mixture of ODE and tetracosane as the 
noncoordinating solvents. The corresponding free fatty acids were added into the system to tune 
the activity of the metal fatty acid salts. The size control of the Fe3O4 nanoparticles was realized 
by varying the concentration and/or the chain length of the fatty acids when the monomer 
concentration was fixed. In simple terms, the higher the ligand concentration is, the larger the 
size of the nanocrystals will be. This is because the ligand concentration greatly affects the 
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monomer reactivity in noncoordinating solvents, while the tunable reactivity of the monomers 
enables a balanced nucleation and growth which is the key to the control of size and size 
distribution[10]. The size remains at a fixed value when relatively long chain fatty acids like 
oleic acid or steric acid were used. However, an increase in particle size was observed, along 
with the acceleration in the overall reaction rate, when the chain was shortened in fatty acids. 
The researchers found that by adding activating reagents, primary amines or alcohols, the 
formation of nanocrystals was significantly accelerated. This is consistent with the increased 
reactivity coefficient of the precursors. Peng also stated that maintaining a balance between the 
nucleation and growth stages to prepare fine nanoparticles is better achieved by introducing 
noncoordinating solvent[8]. In noncoordinating solvents, the reactivity of precursors can be 
tuned by varying the bonding strength of the ligands to the monomers, concentration, chain 
length, and/or configuration of the ligands for the monomers. 
 
 
 
Figure 1. TEM images of as-prepared dot-shaped Fe3O4 nanocrystals. Reprinted (adapted) with permission 
from [8]. Copyright (2004) American Chemical Society. 
 
Sun et al. reported a convenient organic phase process to make Fe3O4 particles with very 
narrow size distribution (i.e., standard deviation < 0.10) and diameter tunable from 3 to 20 nm 
[11, 12], as shown in Figure 2. Under high-temperature (265°C), the reaction of iron (III) 
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acetylacetonate, Fe(acac)3, in phenyl ether in the presence of alcohol, oleic acid, and oleylamine 
can be used to make monodisperse magnetite nanoparticles. It was found that 1,2-hydrocarbon 
diols, such as 1,2-hexadecanediol, react well with the precursor, and both oleic acid and 
oleylamine are necessary for the formation of Fe3O4 particles. Larger particles can be made via 
seed-mediated growth starting with as-synthesized small nanoparticles as seeds[13]. Sun 
indicated that the key to successfully prepare monodisperse nanoparticles is to heat the reaction 
mixture at 200°C before starting reflux in phenyl ether at 265°C, which indicates that under this 
reaction condition, the nucleation and growth of nuclei processes are not fast as demonstrated 
above[12]. 
 
 
 
Figure 2. TEM bright field images of (A) 6 nm and (B) 12 nm Fe3O4 nanoparticles. Reprinted (adapted) 
with permission from [9]. Copyright (2004) American Chemical Society. 
 
Particles as prepared, precipitated and dispersed in organic phase are sterically stabilized 
by the fatty acid and surfactants. The functionalization methods to convert hydrophobic 
nanoparticles to hydrophilic ones will be discussed in the following chapter. 
 9 
 
After reviewing various approaches for monodisperse nanoparticle synthesis, this high 
temperature organic phase procedure that Sun et al[12] reported was utilized in our cancer cell 
destruction project to prepare the ultra-small nanoparticles (SPION) due to its low cost and high 
yields, in addition to the advantage of size-tunable technique. 
1.1.1.2 Hydrothermal synthesis 
Even though the synthesis strategies discussed in thermal decomposition can produce nearly 
monodisperse nanoparticles as the most desired feature, the conditions including the preheating 
step, relatively high reaction temperature (for example, 265°C in Sun’s procedure[12]), and inert 
atmosphere are not very convenient. Alternatively, hydrothermal synthesis, which includes 
various reactants in a sealed container at high vapor pressure (generally in the range from 0.3 to 
4 MPa) and high temperature (generally from 130 to 250 °C), is more convenient. It is prone to 
obtain the highly crystalline iron oxide nanoparticles since grains formed in hydrothermal 
synthesis have a higher crystallinity[14]. Instead of using organic compound as solvent, 
hydrothermal synthesis is usually in a water-ethanol aqueous solution. 
Li et al. developed a general procedure to synthesize monodisperse ferrite microspheres, 
which produces particles with diameters of about 200–800 nm using hydrothermal reduction[15]. 
The system consists of FeCl3, ethylene glycol, sodium acetate, and polyethylene glycol. The 
mixture was first stirred to form a clear solution, then sealed in Teflon-lined-stainless-steel 
autoclave and heated at 200°C for various periods of time. With constant precursor concentration 
and temperature, the diameter of the microsphere was observed to be increasing from 200 nm (at 
8 h) to 800 nm (at 72 h). The components of reaction mixture in this system were skillfully 
designed: ethylene glycol, as part of the family of polyol, is the reducing agent with high boiling 
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point; sodium acetate salt can prevent particle agglomeration by electrostatic stabilization; last 
but not least, polyethylene glycol works as the surfactant also inhibiting agglomeration. 
Interestingly, Li claimed that[15], in their system, NaOAc seemed to assist in the ethylene glycol 
mediated reduction of FeCl3 to Fe3O4, as it showed that Fe3+ could not be reduced solely by 
ethylene glycol under the same reaction conditions in the control experiment. The magnetic 
particles prepared from Li’s synthetic strategy could remain in suspension for more than 1 day 
after being suspended in doubly distilled water by sonication, which demonstrates a great 
systematic colloid stability. 
This study conducted by Li’s group showed that the microsphere size is controllable with 
diameters ranging from 200 to 800 nm using the hydrothermal synthetic strategy. These 
microspheres are colloidal stable and very hydrophilic, which made them good candidates for 
clinical diagnosis and in the transport of drugs, proteins after proper surface modification. The 
raw materials used in this synthesis method are inexpensive and the yields are ~92 %, which is 
relatively high. Therefore, these microspheres can be of great use in biomolecular separations, 
targeted drug delivery, cancer diagnosis and treatment, as well as MRI[15]. 
As for the cell separation project, we modified Li Group’s strategy[15] by adding 
polyacrylic acid (PAA) as to meet our need for the subsequent modification with poly(N-
isopropylacrylamide) (pNIPAM) on particle surface, since the carboxyl groups from PAA are 
able to react with the amine groups on the temperature-responsive polymer, pNIPAM terminated 
by –NH2. Therefore, PAA acted both as a ligand and a surface functionalization agent in this 
solvothermal reaction system. Details of the synthesis, characterization, and the subsequent 
modification and application in multistage cell separation of the PAA-MNP will be described 
and discussed in chapter 3.0. 
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1.1.2 Stabilization 
Maintaining the stability of particles from precipitation and oxidation from air is important after 
successful synthesis[1]. Therefore, protection to obtain physically and chemically stable colloidal 
system is crucial for any application of magnetic nanoparticles. At the same time, 
functionalization of particles for further conjugation with linkers or biomolecules can also be 
achieved through selected coating processes. Basically, all the coating strategies are to form a 
core-shell structure. The coating layer, i.e. the shell, protects the naked core (magnetic particle) 
from the environment where oxidation of Fe2+ and acid erosion could occur and induce damage 
to both particles and the colloidal system. Current coating strategies roughly fall into two major 
categories: organic coatings from surfactants/polymeric stabilizer, such as dextran[16], 
poly(ethylene glycol) (PEG)[17], etc.; inorganic shells from silica[18], carbon[19] or precious 
metals like Ag[20], Au[21]. 
Polymeric materials used as stabilizers act like a barrier between particles by absorption 
onto particle surface to provide steric repulsion. An amphiphilic copolymer, which bears a 
hydrophilic segment to spread into aqueous phase and a hydrophobic segment to anchor on the 
particle surface, provides the most efficient repulsion. If a polymer chain is charged, the 
additional electrostatic repulsion will further stabilize the particles[22]. A few characteristics of 
polymer stabilizer should be taken into consideration when the coating for MNPs is designed. 
For example, the chemical structure determines the biodegradability and 
hydrophilic/hydrophobic property; the conformation contributes to the overall size of the colloid, 
which plays an important role in minimizing the rapid blood clearance; the geometric 
arrangement and degree of surface coverage; the attachment mechanism (covalent or ionic 
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binding, hydrophobic interaction), etc. Researchers found that hydrophilic polymeric coatings 
may increase the plasma half-life resulting from the stealth properties of the shell[23, 24]. PEG is 
the most widely used hydrophilic polymer that is non-toxic and has great steric repulsive 
properties[25, 26]. PEG chain can be attached to MNPs by various approaches, such as 
polymerization at the particle surface[27], modification via sol-gel[28], and silane grafting[29]. 
Polysaccharide dextran has also been used on MNPs coating for in vivo imaging purpose[30]. 
Silica may also facilitate the stability and functional design by introducing alkoxysilanes (for 
example, 3-aminopropyltriethoxysilane)[31]. The advantage of SiO2 coating is that it is easy to 
synthesize and its great stability in aqueous phase[32].  
Alternatively, particles can be dispersed in a dense matrix (like polymer, silica or carbon) 
to form particle composites, which consist of a polymer matrix or a reservoir system[33, 34]. In 
this case, the polymeric shells that avoid size growth after nucleation can create repulsive force 
to balance the magnetic and the van der Waals attractive forces on particles. Surfactants and 
polymers that are either physically absorbed or chemically tethered to particle surfaces work 
similarly as the polymeric shell in particle composites to create repulsion to obtain the colloidal 
stability. Polymeric shell not only provides improved water dispersity and colloidal stability, but 
also introduces functional groups, such as amine and carboxyl groups to the surface. Relevant 
research using gelatin[35], poly(acrylic acid) (PAA)[36], poly(D,L-lactide)(PLA)[37, 38], 
poly(D,L-lactide-co-glycolide)(PLGA)[39-41] has been conducted for encapsulation of MNPs. 
Senna et al found from the XRD diffraction pattern that crystallinity of the particles decreased 
with increasing poly(vinylalcohol) (PVA) concentration[42], indicating defects in the crystal 
structure might occur due to the presence of polymer or copolymer during the nucleation and 
 13 
 
growth. This may affect the magnetic features of MNPs, so that caution should be exercised for 
the selection of stabilizers. 
Another way of particle stabilization is by encapsulating magnetic particles into 
liposome, which is a spherical vesicle used for administration of pharmaceutical drugs[43, 44]. 
Liposomes are mostly phospholipids with at least one lipid bilayer in aqueous solution[45]. A 
liposome has an aqueous core surrounded by a hydrophobic membrane. As a result, hydrophilic 
solutes dissolved in the core cannot pass the bilayer. The fact that liposomes can fuse with cell 
membrane, which is also a bilayer, provides great potential for drug delivery to a specific site, 
even though this process is not spontaneous[46]. Similar to encapsulation into polymeric shell, 
surface functionalization can be realized by liposomal methodology without modification of the 
MNP core, which makes the stabilization process convenient. Joniau et al. studied the adsorption 
of different phosphatidylglycerols onto MNPs in this liposomal magnetic system (also known as 
magnetoliposome) [47]. The bilayer configuration of magnetoliposome is formed with a quick 
absorption of inner monolayer orientated to MNP surface, followed by a much slower assembly 
of outer layer through interactions with the exposed hydrocarbon chains. The kinetics results 
showed that 30%-35% of the adsorption occurs within the first minute, which can be attributed to 
the high binding affinity character of the inner layer adsorption. The adsorption beyond the high-
affinity zone was demonstrated to obey the Langmuir expression (shown in Figure 3): 
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where  is the molar number of lipid adsorbed per gram of Fe3O4 in the Langmuir zone, is 
the number at saturation, c is the phospholipid equilibrium concentration and  is the 
association constant. 
 
 
 
Figure 3. The adsorption of the outer layer on MNP surface beyond the high-affinity zone obeys the 
Langmuir adsorption isotherms. Reprinted by permission from Springer Nature[47] COPYRIGHT (1988). 
 
Instead of incorporating magnetic particles into the aqueous interior of a vesicles during 
the preparation, Cuyper et al. developed another approach to adsorb a phospholipid bilayer onto 
the particle core that were already surfactant-coated[45]. Briefly, phospholipid was vacuum dried 
from the solvent chloroform and dispersed in TES buffer (4mM, pH 7.0), then sonicated to form 
small unilamellar vesicles. Afterwards, solid lauric acid was added to stabilize MNPs and 
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maintained at 90 ºC to improve the solubility of the detergent. Finally, the lauric acid was 
substituted by phospholipids using dialysis of Fe3O4 - lauric acid complex in the presence of 
vesicles for 3 days at 37 ºC. The author claimed that the encapsulation following this protocol for 
the preparation of magnetoliposomes could be considered to be 100%, since all the MNPs were 
found to be covered by a phospholipid bilayer. 
1.1.3 Special features and biomedical applications 
Controllable size and unique properties make iron oxide magnetic particles ideal candidates in 
plenty of biomedical applications. Firstly, owing to various and advanced synthesis 
methodology, the size of iron oxide particles may range from a few nanometers to tens of 
micrometers, which are comparable to the size of a cell (10 – 100 µm), a bacteria (0.2 – 10 µm), 
a virus (20 – 450 nm), a protein (5 – 50 nm) or a gene (2 nm wide and 10–100 nm long)[48]. 
This controllable size allows the particles to easily interact with or bind to almost any biological 
entity of interest. Moreover, the magnetic property of iron oxide [Fe3O4 and γ-Fe2O3 (one 
common form of Fe2O3, cubic structure)] allows particles to be manipulated remotely by external 
magnetic field gradient. By applying external magnetic fields and letting them penetrate into a 
particular tissue, magnetic nanoparticles, or magnetically tethered biological entities can be used 
to transport and/or immobilize drug vehicle, such as anticancer drug (doxorubicin)[49], or a 
cohort of radionuclide atoms to a targeted region of the body[50]. Third, the magnetic 
nanoparticles can resonantly respond to a time-varying magnetic field transforming 
electromagnetic energy from the high-frequency field to heat. In this case, particles can be heated 
up, providing the application opportunity as hyperthermia agents, delivering toxic amounts of 
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thermal energy to targeted bodies such as tumors; or as chemotherapy and radiotherapy 
enhancement agents, where a moderate degree of tissue warming results in more effective 
malignant cell destruction. The applications discussed above are made possible in biomedicine as 
a result of the special physical properties of magnetic nanoparticles. 
 
 
 
Figure 4. Nanoscale size effect of WSIO nanocrystals on magnetism and induced MR signals. (a) TEM 
images of Fe3O4 nanocrystals of 4 to 6, 9, and 12 nm. (b) Size-dependent T2-weighted MR images of WSIO 
nanocrystals in aqueous solution at 1.5 T. (c) Size-dependent changes from red to blue in color-coded MR images 
based on T2 values. Reprinted (adapted) with permission from [51]. Copyright (2005) American Chemical Society. 
 
Cheon et al. investigated the effect of nanoparticle size on MRI signal intensity for their 
utilization in cancer diagnostics[51]. Highly monodisperse (σ = ∼5%) water-soluble iron oxide 
nanoparticles with sizes of 4, 6, 9, and 12 nm using the thermal decomposition of Fe(acac)3 were 
first synthesized, and then demonstrated the correlation between the particle size and magnetism 
by measuring the mass magnetization values. It is shown that as magnetic particle size increases, 
the T2-weighted MR signal intensity continuously decreases[51], as shown in Figure 4. 
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1.1.3.1 Gene and Drug Delivery 
The idea of using magnetic particles to deliver therapeutic agents, such as gene and 
pharmaceutical agents, was first proposed in the late 1970s by Widder et al.[52]. The basic 
concept of magnetic drug delivery is to attach the magnetic nanoparticles to the drug, and thus to 
target at a specific site guided by the localized magnetic field. The drug-loaded magnetic 
particles can be held at the therapy location until the therapy is complete or the local 
concentration is high enough, which minimizes the side effects and toxicity in other normal 
organs and tissues. The therapeutic molecules can be attached to, or encapsulated within a 
vehicle which may be a core-shell structured magnetic particle with polymer coatings, or may be 
in the form of porous polymers with magnetic nanoparticles precipitated in the pores[53]. By 
modifying the polymer coating, drugs for targeted chemotherapy or therapeutic DNA to fix a 
genetic defect can be attached to magnetic particle carriers. Several approaches have been 
applied to attach the agents to particle, including conjugating cleavable linkers[54], incorporating 
therapeutic molecules into degradable shell, or simply taking advantage of electrostatic 
interactions between the positively charged particle surface and negatively charged backbone of 
DNA[55].  
Even though the targeted drug delivery enabled by magnetic particles has been proven to 
be successful in many studies[32, 52, 53, 56], only a small number of clinical trials have been 
performed to date. A trial performed in 2004 examined the efficacy of magnetic targeted carrier 
bound to doxorubicin (MTC-DOX) for the treatment of four patients with inoperable 
hepatocellular carcinoma[57]. In this study, doxorubicin was absorbed to composite 
microparticles made from metallic iron and activated carbon following the Langmuir theory[58]. 
MTC-DOX was delivered via the hepatic artery using concurrent MR imaging to monitor, and 
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interim catheter manipulation was performed with fluoroscopic guidance to optimize delivery to 
the tumor and minimize the effects on normal tissue[57]. The particles were targeted to the tumor 
sites by using rare earth magnets placed on the body surface. The results indicated that the MTC-
DOX microparticles were well targeted at the tumor sites with the tumor volumes shrinking 
down to 64%–91% of the originals, while the affected normal liver volume only ranged from 
7%–30%. Despite of the drawbacks of the long duration of the treatment sessions, the expense of 
obtaining multiple MR images and the abnormal pain reported by all four patients, this study has 
provided very important information for future research in magnetic particle facilitated drug 
delivery. 
1.1.3.2 Hyperthermia 
Magnetic hyperthermia is an experimental treatment for cancer based on the fact that magnetic 
nanoparticles can transform electromagnetic energy from an external high-frequency field to 
heat. Hyperthermia is considered a supplementary treatment since a small temperature rise 
makes cancer cells more susceptible to radiation and chemotherapy[59]. The biological basis of 
hyperthermia is that temperature rise (to 40–45°C) initiates a series of subcellular events, 
rendering the cells susceptible to apoptosis or other forms of damage, leading to subsequent cell 
death. Because of the low efficiency of blood flow and oxygen transport through newly formed 
blood vessels within tumors, tumor cells in an acidotic and nutrient-deprived setting tend to be 
more thermosensitive[60]. Previous studies showed that intravenously injected nanoparticles 
prefer to accumulate in tumors rather than in normal tissues, which is often referred to as the 
enhanced permeability and retention (EPR) effect[61]. Therefore, when magnetic particles are 
exposed to alternating magnetic fields, heat is generated at tumor site from magnetic hysteresis, 
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Neel-relaxation and Brown-relaxation[62]. Tumor-targeted nanoparticles results in less non-
specific accumulation in the other part of body, enabling a lower dosage for an equal therapeutic 
effect and a decreased toxicity induced by nanoparticles. A monolayer of PEG covering 
polymeric dextran shell could enhance the circulation half-life[63] to prevent bare iron oxide 
particles from being cleared from blood too fast and accumulation in liver, spleen and lymph 
instead of tumor[59]. To achieve adequate concentrations in the tumor, magnetic nanoparticles 
are modified by targeting molecules like peptides and antibodies. Triton BioSystems, Inc. 
(Chelmsford, MA) developed the system of alternating magnetic field (AMF) responsive 
nanoparticles and targeted these to cancerous tissues by conjugating with monoclonal 
antibodies[59]. The degree of heating is controlled by the AMF field. However, increasing the 
AMF field strength generates heat in normal tissues from eddy current losses. Therefore, the 
raised temperature in the normal tissues limits the extent to which the AMF field can be 
increased[64]. 
1.1.3.3 Diagnostic: MRI contrast 
MRI is one of the most powerful non-invasive imaging modalities utilized in hospitals and 
clinics for medical diagnostic[65]. The process through which the hydrogen protons return to 
their original state from the alignment to the applied magnetic field is termed the relaxation. 
Longitudinal relaxation (T1) and transverse relaxation (T2) are two independent processes, 
which can be monitored to generate an MR image. Proton density, as well as the nature of the 
tissues, determines the local variation in relaxation, corresponding to image contrast. MNPs 
provide MR contrast enhancement when accumulated in tissues[56]. This ability of MNPs to 
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serve as MR imaging contrast agents provides great detection and diagnostics opportunities in 
cancer imaging, cardiovascular disease imaging and molecular imaging [30]. 
Helmberger et al. demonstrated that imaging of liver tumors and metastases through 
RES-mediated uptake of SPION is able to distinguish lesions as small as 2–3 mm[66]. Moreover, 
ultrasmall superparamagnetic iron oxide nanoparticles(USPIOs) have been proven effective 
identifying lymph node metastases with a diameter of 5–10 mm under MRI[67]. Another 
promising usage of MNPs in cancer therapy is to improve the delineation of brain tumor 
boundaries and quantify tumor volumes[68]. This is because MNPs improved cellular 
internalization and were cleared more slowly from tumor site, which prolonged the delineation of 
tumor margins[69]. 
1.1.3.4 Magnetic Assisted Separation 
Magnetic particles have been proven to be effective and useful in magnetic-driven separation of 
biochemical products like protein, DNA, and cells[70-73]. It is a reliable and simple method to 
efficiently capture specific biomolecules from mixtures by applying external magnetic field. The 
unique superparamagnetic feature that magnetic particles in certain sizes have is of great usage 
since they can be magnetized from the external magnetic field and resuspended immediately as 
soon as the magnetic field is removed. 
Xu et al. used dopamine (DA) as a novel anchor to immobilize functional molecules, 
nitrilotriacetic acid (NTA), on the iron oxide shell of magnetic nanoparticle, which exhibits high 
specificity and capacity for histidine-tagged protein purification from cell lysate[70]. The 
average sizes of M/Fe2O3 synthesized are 8.5 nm and 9.5 nm when the cores of nanoparticle are 
Co and SmCo5.2, respectively. Dopamine was chosen to be the anchor on Fe2O3 shell for two 
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main reasons. Firstly, the bidentate enediol ligands of dopamine can convert coordinatively 
unsaturated Fe surface sites to a bulk-like lattice structure[74], which may result in high binding 
affinity of dopamine to Fe2O3 shell. Secondly, Langmuir isotherms indicate that the adsorption of 
dopamine from Fe2O3 nanoparticles is more favorable than desorption[75]. After removing the 
physically absorbed proteins on M/Fe2O3-DA-NTA-Ni2+ particles by deionized water, 10 and 
500 mM of imidazole elutions were used to sequentially wash the protein-bound nanoparticles. It 
is shown in Figure 5A that only the target protein (6xHis-GFP, lanes 4, 5, and 7) existed in the 
imidazole elutions. In addition, electrophoresis traces in Figure 5B show that the fractions 
washed from the particles with SmCo5.2 core that had been boiled in Tris buffer (pH = 7.9) for 
20 min contain only the histidine-tagged protein, indicating the specificity and efficiency the 
particles remain unaffected from heating[70]. 
 
 
 
Figure 5. SDS/PAGE analysis of the purity of the proteins. (A) Cell lysate (lane 1), GFP standard (lane 2), 
molecular weight marker (lane 3), the fractions from freshly made SmCo5.2/Fe2O3−NTA by washing with imidazole 
elutions (10 mM, lane 4; 500 mM, lane 5), fractions from the freshly made Co/Fe2O3−NTA using imidazole 
elutions (10 mM, lane 6; 500 mM, lane 7). (B) Cell lysate (lane 1), GFP standard (lane 7), the molecular weight 
marker (lane 8), the fractions washed from the freshly made 6b (lanes 2 and 3), boiled 6b (lanes 4 and 5), and the 
microbeads of the commercial HiTrap affinity column (lanes 6 and 9). The concentrations of imidazole are 10 mM 
(lanes 2, 4, and 6) and 500 mM (lanes 3, 5, 9). Reprinted (adapted) with permission from [70]. Copyright (2004) 
American Chemical Society. 
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Magnetic nanoparticles have also shown great capabilities in gene separation due to their 
high separation efficiency[71]. Separation of rare DNA/mRNA targets from complex matrix is 
critical in diagnostics, gene expression studies, and gene profiling. Weihong Tan et al. developed 
a novel genomagnetic nanocapturer (GMNC) for collection, separation, and detection of trace 
amounts of DNA/RNA molecules with one single-base difference[72]. The GMNC was coated 
with silica as the protection layer, where avidin-biotin was used as linkers to conjugate the 
molecular beacon DNA probes onto the particle surface. After being evaluated in both artificial 
buffer solution and in cancer cell samples containing different proteins and random DNA 
sequences, the GMNC was demonstrated to be highly efficient in collection of trace amount of 
DNA/mRNA samples down to femtomolar (10-15 M) concentrations. This newly developed 
genomagnetic nanocapturers have exceptional feature of real-time monitoring and product 
collection as well, which provides plenty of future application opportunities in gene separation. 
1.2 CANCER TREATMENT BY REACTIVE OXYGEN SPECIES 
Reactive oxygen species (ROS) are a wide range of critical signaling molecules[76, 77]. When 
the unpaired electron of oxygen reacts with other molecules, the partially reduced highly reactive 
products formed are defined as ROS. ROS consist of a group of chemicals, including superoxide 
anion radical, singlet oxygen, hydrogen peroxide and the hydroxyl radical. ROS can be produced 
from several enzyme systems, including the mitochondrial electron transport chain, cytochrome 
P450, lipoxygenase, cyclooxygenase, the NADPH oxidase complex, xanthine oxidase, and 
peroxisomes[78]. Among those systems, mitochondrial oxygen metabolism is the major source 
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of superoxide resulting from the electron transport chain. The hydroxyl radical, •OH, is the 
neutral form of the hydroxide ion (OH-). The high reactivity of hydroxyl radical makes it a very 
destructive radical with a short half-life of approximately 10-9 s[79], which mostly leads to local 
reactions at the site where it is formed shortly beforehand. 
ROS act as a second messenger in cell signaling and essentials for biological processes in 
normal cells, while they are ironically considered harmful to cells, tissues and organisms 
meantime[80]. ROS are physiologically produced intracellularly through multiple mechanisms 
depending on the cell type. The major process, oxidative phosphorylation in which adenosine 
triphosphate (ATP) is produced, involves the transport of protons via the electron transport 
chain. Electrons are transferred through proteins via redox reactions, and finally to oxygen 
molecule. In most cases, the oxygen is fully reduced to water by gaining four electrons; however, 
oxygen can sometimes be partially reduced to produce the superoxide radical (•O2−), the 
hydrogen peroxide (H2O2), and hydroxyl radical (•OH) by receiving one, two, three electrons, 
respectively[81]. ROS can also be generated by exogenous sources like radiation, and 
pathologically by inflammation of metal such as copper and iron. In human body, iron normally 
binds to transferrin, which is blood plasma glycoproteins that control the concentration of 
free iron in the blood[82]. When iron is not bound, it will generate ROS, particularly the most 
reactive hydroxyl radicals, via Fenton’s reactions[83]: 
Fe2+ + H2O2 Fe3+ +  OH+OH
Fe3+ + H2O2 Fe2+ +  OOH+H  
ROS level is usually maintained very stable by scavenging systems, in which such ROS 
are involved in cell signaling[84]. Whereas redox balance, the ratio between oxidizing and 
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reducing species within cells, is achieved by a few enzyme systems that neutralize toxic oxidants 
like ROS. For example, superoxide dismutases (SOD) can catalyze the reaction of •O2− to H2O2, 
and subsequently H2O2 is converted to H2O by gluthathione (GSH) peroxidase coupled with 
glutathione reductase[85]. A slight increase in ROS level may induce higher cell proliferation 
and differentiation rates, while a significant ROS stress resulting from the exogenous agents can 
overwhelm the relatively low antioxidant capacity and disrupt the redox homeostasis inside 
cancer cells, and cause damage to proteins, lipids and DNA, which can lead to cellular damage 
and death[86-88], as shown in Figure 6. 
 
 
 
Figure 6. Influence of ROS exposure level on cell sinaling. Reproduced from [85], Copyright 2007 with 
permission from AACR. 
 
DNA damage mediated by ROS plays an important role in carcinogenesis initiation and 
malignant transformation[89]. Hydroxyl radicals may react with pyrimidines, purines, and 
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chromatin protein, causing base modifications, genomic instability, and alterations in gene 
expression[85]. Chronic inflammation or chronic chemical irritants like tobacco smoking can be 
some pathologic sources of transforming ROS[90]. Due to the shortage or absence of cell cycle 
checkpoints, and the overexpress in oncogene growth factors and the receptor tyrosine, 
transformed cells ultimately end up with tumor formation and chronic hypoxia[91]. Inhibition of 
protein phosphatases caused by H2O2 induces proliferation and apoptosis suppression, and also 
associates oncogene overexpression with ROS-mediated signaling[92]. Abnormal cell 
proliferation driven by oncogene growth factor activation and signal transduction requires larger 
amount of oxygen which is beyond the capacity of the resting vasculature, and therefore 
stimulates the development of new blood vessels[93]. 
Among all the reactive oxygen species, the hydroxyl radical is extremely reactive 
because it is able to propagate a chain reaction by removing electrons from any molecule in its 
path, and turning that molecule into a free radical, which makes it the most damaging radical. 
Cancer cells are known for an exhibition of increased intrinsic oxidative stress. Therefore, the 
high level of ROS in cancer cells has provided opportunity to develop new therapeutic strategy 
to preferentially kill cancer cells rather than both the cancer cells and the healthy cells in current 
cancer treatments[94]. 
There are a few common approaches to generate ROS in current clinical research, 
including radiotherapy, photodynamic therapy and chemotherapy. During radiotherapy, there is a 
massive boost in ROS level initiated by X-rays, γ-rays, or heavy particle radiation such as 
protons and neutrons. However, concerns about the healthy tissue damage and radiation safety 
have been restricting the application of radiation therapy to a very large extent[95-98]. Whereas 
photodynamic therapy (PDT) uses ROS generated by irradiating nontoxic photosensitizer with 
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appropriate light in the presence of molecular oxygen to destroy tumor cells[99-101]. Even 
though the principle is simple, it is difficult and challenging to control the dose of drug and light, 
as well as the interval between drug and light administration[99, 102-104]. Moreover, PDT is 
limited by the penetration depth of the light that excites the photosensitizers. 
Recently, a few studies utilized SPION in combination with ROS-based anticancer drugs 
to potentially improve drug targeting specificity and therapeutic efficacy in theranostic 
nanomedicine platforms for multimodal cancer image-guided cancer therapy[105, 106]. 
As described above, increased ROS level leads to enhanced cell proliferation and 
apoptosis suppression, therefore modulation of ROS to a certain level can be used as a 
therapeutic strategy in cancer therapy. The pathways in which ROS are increased in malignant 
cells are oncogene signaling via the NADPH oxidase complex and by hypoxia-related 
mitochondrial ROS. Therefore, two therapeutic approaches targeting the pathways are 
considered: (a) increasing ROS scavenging, thereby reducing H2O2 signaling and restraining 
tumor growth; (b) interfering with ROS scavenging within cells, causing excess ROS 
accumulation therefore triggering apoptosis[107, 108]. 
Cullen et al.[109] showed evidence to support that increasing ROS scavenging could be a 
promising therapeutic strategy using ROS. They investigated if the overexpression of 
phospholipid glutathione peroxidase (PhGPx), which decreases lipid hydroperoxides from 
biomembranes, could change pancreatic tumor cell behavior. Both mitochondrial PhGPx form 
(L-form) and nonmitochondrial PhGPx form (S-form) were used in the synthesis of adenovirus–
PhGPx (L/S-form) construct. In the nude mice with pancreatic cancer cells implantation model, 
AdPhGPx-L- form decreased in vivo tumor growth to a greater extent than did AdPhGPx-S-
form. Meanwhile, AdPhGPx-S-form demonstrated 80% tumor growth inhibition in vitro, 
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whereas AdPhGPx-L-form demonstrated 95% tumor growth inhibition. This growth-inhibitory 
effect showed that overexpression of glutathione peroxidase could depress tumor growth both in 
vitro and in vivo in mouse models. 
On the other hand, interference with ROS removal can also result in the accumulation of 
excess ROS, which leads to apoptosis by triggering mitochondrial to open permeability transition 
pore and release pro-apoptotic factors[110]. ROS are one of the most efficient activators of the 
PTP for apoptosis[111]. When ROS are generated, Ca2+, a potent stimulus for the PTP, is 
released from both intracellular stores and the extracellular environment [112], which put tumor 
cells under oxidative stress as well as a greater risk from the cytosolic calcium. Chandra et al 
stated that tumor cells which are resistant to chemotherapy drugs can isolate Ca2+ more 
efficiently[113]. The tumor cells also show a reduction in the release of Ca2+ from intracellular 
storage sites once apoptosis is inducted. Thus, these tumor cells are less sensitive to the 
stimulation caused by Ca2+. 
A platform that enables singlet oxygen (1O2) generation at specific tumor site for cancer 
cell destruction has been developed by Chen et al.[106] to show evidence of feasibility of ROS 
used as therapeutic agents in cancer treatment. The system was based on a reaction similar to 
Fenton reaction discussed above between linoleic acid hydroperoxide (LAHP) attached to iron 
oxide nanoparticles and the ferrous ions released from the particles under acidic condition. This 
system has been shown to lead to apoptosis of U87MG cell line both in vitro and in vivo through 
1O2 generation at tumor site and ROS mediated mechanism. This study[106] provided important 
evidence that moderating ROS level by introducing external ROS source can be a feasible 
approach for tumor specific cancer treatment. 
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1.3 CANCER PROGNOSIS BY ISOLATION AND ANALYSIS CIRCULATING 
TUMOR CELLS (CTC) 
Despite of the advanced techniques in surgery, metastasis is still one of the most critical 
problems that affect the prognosis of cancer patients[114]. During metastasis, tumor cells are 
detached from the original site and shed into the bloodstream, then arrested in the small vessels. 
These so called circulating tumor cells (CTCs) can finally grow into secondary tumors after they 
successfully survived from the host defense mechanisms and establish a microenvironment. In 
other words, CTCs are the seeds for subsequent growth of additional tumors in fairly distant 
organs, resulting in the majority of cancer-related deaths. 
It is clinically important to find out a way detecting a small quantity of CTCs in the 
relatively large amount blood sample. In previous studies, disseminated tumor cells in peripheral 
and mesenteric venous blood were detected by conventional cytology or immunocytological 
methods using monoclonal antibodies (mAbs) to cytokeratin (CK) or epithelial cell membrane 
markers[115-117]. However, these staining methods are too complicated for routine use, and the 
sensitivity was limited by the low analysis capacity. Developments in molecular technology have 
made it possible to detect small numbers of tumor cells in the peripheral blood, and several 
reports have described the usefulness[42, 47]. 
In addition to capturing CTCs from blood, cell separation processes also have broad 
application in isolation of immune cells from peripheral blood, isolation of white blood cells 
from tissue, and food industry such as separation of pathogenic bacteria from food. Three 
different cell separation approaches, which are classified based on if the cell type of interest is 
targeted and retained for subsequent analysis, include positive selection, depletion, and negative 
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selection[118]. With positive selection, the cell of interest is targeted by the removal mechanism 
and retained for downstream analysis. This typically is enabled by targeting a cell surface marker 
like receptor or antigen with a monoclonal antibody or peptide[119]. Alternatively, depletion is 
to remove a single cell type from a biological mixture. For example, removal of red blood cells 
(RBCs) from peripheral blood mononuclear cells (PBMCs)[120]. Similar to depletion, when 
several cell types are removed to leave only one cell type remained, it is called negative 
selection, for instance, depletion of all cells except for T-Cells, or removal of all cells except for 
B-Cells, from samples like whole blood or bone marrow[121]. Currently, various cell separation 
technologies have been studied and developed commercially, including fluorescence activated 
cell sorting (FACS), magnetic activated cell sorting (MACS), buoyancy activated cell sorting 
(BACS) and other technologies, such as microfluidics, centrifugation, and filtration. 
The general idea of fluorescence activated cell sorting (FACS) is based on cell labeling 
with fluorescent markers, either internal or external markers of the cells. The cells are then 
measured and identified one at a time and then sorted based on the fluorescence signal generated 
from the marker using flow cytometry. Flow cytometry is a very informative and powerful 
method for the analysis and separation of cell populations. Its strength is to measure multiple 
parameters quantitatively from statistically adequate numbers of cells to define the properties of 
a cell population or its component subpopulations[122]. FACS can be widely utilized for cell 
separation thanks to the monoclonal antibodies, which have greatly increased the range and 
effectiveness of immunofluorescence measurements. Herzenberg et al.[123] reported in the 
1960s that they used intracellular fluorescence, which was developed from fluorochromasia after 
exposure to fluorescein diacetate, as the sorting parameter for separation of cultured Chinese 
hamster ovarian (CHO) tumor cells from mouse spleen cells. The intracellular fluorescence in 
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CHO was realized by incubating the CHO live cells with fluorescein diacetate, which can enter 
the cells and be hydrolyzed by intracellular esterases. Since the fluorescein generated cannot exit 
the cell membrane, the CHO cells are able to show fluorescent signal when illuminated by the 
appropriate exciting beam, thus can be detected and analyzed in the flow cytometry. The method 
was also used to sort highly fluorescent fractions with similar procedure from mouse spleen cells 
immunized to sheep erythrocytes. The enrichment factor in antibody-producing cells reached 4 - 
10. 
FACS facilitated with flow cytometry is overall a rapid and simple procedure to sort and 
analyze cell populations. Appropriate combinations of fluorescence labeling and exciting 
wavelengths allow us to evaluate multiple parameters on each cell, and therefore to distinguish 
between cell types in mixed cell populations, or to assess the relationships between each cellular 
variable[124]. Taken the requirement to avoid coincidence counting and mechanical damage to 
the cells into consideration, the factors of the cell concentrations in the sample and linear flow 
rates usually yield that mostly 100 to 1,000 cells s-1 are analyzed by the instrument, which 
renders FACS a very high-speed analysis technology. The requirement of single cell suspensions 
for flow cytometry may pose certain limitations on its applicability, in addition to a substantial 
cost on the instrument[125]. 
Another widely used cell separation method is magnetic activated cell sorting (MACS), 
which is a gentle, fast and promising method for isolating and detecting a small amount of tumor 
cells that are functionally active from the blood circulation by magnetic labeling (shown in 
Figure 7)[126]. The technology is based on magnetic particles, in combination with an external 
magnetic field, a column or magnetic separator or simply a magnet. When a strong enough 
magnetic field is applied, the magnetically labeled cells (target cells) retain in the column, while 
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unlabeled cells pass through, which can be collected as the unlabeled fraction, which are non-
target cells. The retained cells are eluted to form a new solution after removal from the magnet. 
Typically, MNPs are functionalized with a receptor to bind the molecules on the surface 
of the specific cell, and high separation efficiency is enabled by the extremely high binding 
affinity and specificity of the receptor, such as an antibody, immobilized on the MNPs.  
However, a major obstacle that prevents the MACS technology from achieving satisfying 
separation efficiencies is the non-specific interactions between the cells and MNPs. Despite that 
the binding affinity of antibodies to the antigens is orders of magnitude greater than that of the 
nonspecific binding, the effect of nonspecific interactions becomes significant and eventually 
becomes a major challenge in the case of separation processes that require very large enrichment 
factors. 
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Figure 7. MACS separation scheme: ideal vs. realistic. 
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2.0  TARGETED DESTRUCTION OF CANCER CELLS BY GLUCOSE OXIDASE-
IRON OXIDE BIOCONJUGATES 
In this chapter, a platform was designed for ROS induced cancer cell destruction based on the 
fact that a significant increase in ROS level could lead to cell apoptosis and death. The ROS in 
this platform is generated via Fenton’s reaction between Fe2+/ Fe3+ provided by the iron oxide 
nanoparticles and H2O2 produced from glucose. Glucose oxidase and iron oxide were conjugated 
by click chemistry method to form SPION-GOx bioconjugates, which were able to passively 
accumulate in the tumor due to the EPR effect induced by nanoparticles. 
The feasibility of the platform designed above has been demonstrated: 
1) Both FPLC and DLS results showed that the SPION-TCO and GOx-Tz were successfully 
conjugated based on the increase in particle size; 
2) TMB assay indicated that SPION-GOx bioconjugates generate ROS effectively from the 
substrate glucose;  
3) In vitro cell viability assay showed that SPION-GOx bioconjugates efficiently destruct 
tumor cells;  
4) In vivo cytotoxicity assessment indicated that SPION-GOx possess a low toxicity and 
side effect. 
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2.1 INTRODUCTION 
Ultra-small superparamagnetic iron oxide nanoparticles (SPION) are a multi-duty platform with 
the particle diameter <50 nm. Small size enables cellular uptake, extravasation, and tissue 
localization in drug delivery. Smaller particles accumulate in pathological tissues with leaky 
vasculature via the enhanced permeability and retention (EPR) effect[127]. In addition, small 
size results in enhanced accumulation in target organs by minimizing nonspecific clearance in 
reticuloendothelial system tissues like liver and spleen[128].Furthermore, the mechanism of 
cellular uptake and subsequent intracellular routing is also affected by size, with smaller particles 
being internalized via clathrin-coated pits and more likely to reach lysosomes[129]. As a result, 
small particles reach cellular targets more efficiently, but require a mechanism to escape 
lysosomal degradation. While there are benefits of using small nanoparticles, there is also a need 
to give them complex function, so they can overcome obstacles presented by their small size. 
Despite of the fact that SPION have not shown toxicities after cell uptake and cellular 
internalization so far, the biological activities of them have hardly been developed for therapeutic 
applications. SPION are generally considered MRI contrast agents or drug delivery vehicles with 
no intended pharmacological functions. The possibility to modify the surface of the particles 
with biologically active compounds, like antibodies and peptides, enables transport of 
therapeutic agents into specific tumor cells, increasing specificity and avoiding the access of 
cytotoxic agents to healthy tissues during the delivery process. 
Recently, a few studies utilized SPION in combination with ROS-based anticancer drugs 
to potentially improve drug targeting specificity and therapeutic efficacy in theranostic 
nanomedicine platforms for multimodal cancer image-guided cancer therapy[105, 106]. ROS are 
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a group of chemical species (including superoxide anion radical, singlet oxygen, hydrogen 
peroxide and the hydroxyl radical) that act as a second messenger in cell signaling and essentials 
for biological processes in normal cells, while they are ironically considered harmful to cells, 
tissues and organisms meantime[80]. ROS are physiologically produced intracellularly through 
multiple mechanisms depending on the cell types. The major process being the one called 
oxidative phosphorylation in which adenosine triphosphate (ATP) is produced, involves the 
transport of protons via the electron transport chain. Electrons are transferred through proteins 
via redox reactions, and finally to oxygen molecule. In most cases, the oxygen is fully reduced to 
water by gaining four electrons; however, oxygen can sometimes be partially reduced to produce 
the superoxide radical (•O2−), the hydrogen peroxide (H2O2), and hydroxyl radical (•OH) by 
receiving one, two, three electrons, respectively[81]. ROS can also be generated by exogenous 
sources like radiation, and pathologically by inflammation or metal such as copper and iron. In 
human body, iron normally bind to transferrin, which is blood plasma glycoproteins that control 
the concentration of free iron in the blood[82]. When iron is not bound, it will generate ROS, 
particularly the most reactive hydroxyl radicals, via Fenton’s reactions[83]: 
Fe2+ + H2O2 Fe3+ +  OH+OH
Fe3+ + H2O2 Fe2+ +  OOH+H  
A slight increase in ROS level may induce higher cell proliferation and differentiation 
rates, while a significant ROS stress resulting from the exogenous agents can overwhelm the 
relatively low antioxidant capacity and disrupt the redox homeostasis inside cancer cells, and 
cause damage to proteins, lipids and DNA, which can lead to cellular damage and death[86-88]. 
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Among all the reactive oxygen species, the hydroxyl radical is extremely reactive because it is 
able to propagate a chain reaction by removing electrons from any molecule in its path, and 
turning that molecule into a free radical, which makes it the most damaging radical. Cancer cells 
are known for an exhibition of increased intrinsic oxidative stress. Therefore, the high level of 
ROS in cancer cells has led us to develop new therapeutic strategy to preferentially kill cancer 
cells rather than kill the healthy cells simultaneously in current cancer treatments[94]. 
To avoid the healthy tissue damage, radiation safety issue caused by radiation therapy, 
and difficulties in controlling PDT light administration, in the past decades, some therapeutic 
drugs that either generate ROS or inhibit antioxidant enzymes have been investigated for cancer 
treatment [30-32]. Here we propose a new approach for ROS-induced cell destruction through 
passive accumulation of SPION-GOx bioconjugates in cancer cells by producing ROS from 
blood sugar. 
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Figure 8. Schematics for targeted destruction of tumor cells by SPION-GOx bioconjugates. 
 
 37 
 
As shown in Figure 8, The mechanism of the destruction of tumor cells is basically that:  
aggressive tumor cell proliferation induces elevated glucose concentration in tumor[130, 131]; 
H2O2 is released when glucose comes into contact with GOx and it is oxidized to 
gluconolactone; afterwards, H2O2 diffuses to the surface of SPION that catalyzes the production 
of ROS from H2O2; and high level of ROS, especially hydroxyl radicals results in highly 
efficient tumor cell destruction. It should be noted that RGD in this scheme is a peptide that 
specifically binds to the integrin αvβ3. RGD was conjugated onto GOx only when the 
biodistribution of GOx-RGD needed to be determined in this thesis. Cetuximab, a commercially 
available monoclonal antibody was also used in a previous preliminary study as a targeting 
agent, like RGD. 
Our preliminary experimental results indicate this tumor cell destruction platform is 
effective and it could lead to a new cancer therapy with unprecedented low side effect and long-
term effectiveness. In particular, we have demonstrated that GOx and SPION are not effective 
individually. Instead, they need to be conjugated in order to produce ROS in this platform. As a 
result, our strategy is to deliver SPION to tumor site in the first step facilitated by MRI providing 
the intrinsic MRI guidance ability of SPION, and then GOx will initiate production of hydroxyl 
radicals by forming a SPION-GOx bioconjugates. It is noteworthy that both GOx and SPION 
serve as catalysts in this reaction. 
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2.2 METHODS 
2.2.1 Materials  
All solvents and reagents were purchased from commercial sources and used without additional 
purifications, unless otherwise noted. DSPE-PEG (2000)-Amine was obtained from Alvanti 
(Alabaster, AL). The monoclonal antibody Cetuximab (Erbitux, 2.0 mg/mL) was purchased from 
ImClone Systems Incorporated (New York, NY). TCO-(PEG)4-NHS and Tz-(PEG)4-NHS were 
obtained from Fisher Scientific (Pittsburgh, PA). Sulfo Cyanine7(Cy7)-NHS ester was purchased 
from Lumiprobe Corporation (Hallandale Beach, FL). Glucose Oxidase was obtained from 
Crescent Chemical Company (Islandia, NY). All other chemicals and reagents were obtained 
from Sigma Aldrich (St. Louis, MO). 
2.2.2 Synthesis of SPION  
A narrow size distribution of the nanoparticles is the prerequisite for the uniform physical and 
chemical properties for further applications. Based on the prior studies, common methods to 
prepare Fe3O4 nanoparticles smaller than 20 nm include: co-precipitation of ferrous and ferric by 
a base[126, 132], solvothermal reaction of iron salt in a non-aqueous solvent (hexane) in 
presence of oleic acid and laurylamine[133], and thermal decomposition of organo-metallic 
compounds in an organic solvent at high temperature[12]. Hereby, SPION for the tumor cell 
destruction purpose were synthesized in an organic phase according to the method reported by 
Sun with slight modification[12]. Briefly, Fe(acac)3 (2 mmol), 1,2-hexadecanediol (10 mmol), 
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oleic acid (6 mmol), oleylamine (6 mmol), and benzyl ether (20 mL) were mixed and 
magnetically stirred under a flow of nitrogen. The mixture was heated to 200 °C and stirred for 2 
h, followed by reflux (~300 °C) for 1 h in nitrogen environment.  After the reaction mixture was 
cooled down to room temperature, the SPION were precipitated by addition of ethanol into the 
mixture and washed with hexane and ethanol 3 times each. The as-synthesized SPION particles 
were dispersed in hexane. 
2.2.3 Surface functionalization of SPION 
SPION as synthesized from last step were well dispersed in the organic phase. However, SPION 
need to be hydrophilic and suspended in aqueous solution for further linkage and biological 
purposes. To this end, surface coating was applied to alter the hydrophobicity of the particles. 
Herein, the film hydration method was used to coat nanoparticles with a lipid, DSPE-PEG 
(2000)-amine to form micellar nanoparticles, shown in Figure 9. In aqueous solution, DSPE-
PEG (2000) micelles are oblate spheroids with a maximum diameter of 18 nm. DSPE-PEG was 
firmly tethered to the iron oxide core via hydrophobic interaction between DSPE and oleic acid 
or oleylamine. At the free end of the PEG chain, amine groups were also introduced, which 
allowed further linkage to biological ligands[134]. Briefly, the SPION suspension was 
centrifuged to replace the original solvent hexane with chloroform. Subsequently, 40 mg DSPE-
PEG (2000)-amine (25 mg/mL in chloroform) was added to 20 mg SPION (12 mg/mL in 
chloroform). The solvent was evaporated under a blanket of nitrogen to obtain the lipid film. The 
film was further dried in a vacuum chamber overnight to remove the remaining solvent. Finally, 
the coated particles were hydrated in PBS buffer. 
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Figure 9. Stabilization of MNP using lipid DSPE-PEG (2000)-amine. Reprinted (adapted) with permission 
from [134]. Copyright (2010) American Chemical Society. 
 
2.2.4 Determination of SPION concentration and amine density 
The concentration of SPION dispersed in DI water was determined by measuring the Fe3+ 
concentration. After the addition of 12N HCl and 30% w/w H2O2, the mixture was incubated at 
37°C for 2h. After being mixed with 5% KSCN, the absorbance of the resulting sample, which 
showed an intense red color from FeSCN2+, was measured at 480 nm on a Plate Reader, and then 
compared to the standard curve. 
To understand the available sites for the following NHS reactions, the density of primary 
amine on SPION particles after the surface functionalization was determined by a non-
fluorescent reagent, fluorescamin, which reacts with primary amine to form a highly fluorescent 
complex (Excitation / Emission: 365/470 nm). The intensity of the fluorescence signals of the 
sample and standards were measured by BioTek Plate Reader. 
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2.2.5 Preparation of Cy7-GOx-Tz 
Methyltetrazine-(PEG)4-NHS ester (3.0 mg, 6.0 µmol) and Sulfo-Cy7-NHS (3.0 mg, 6.0 µmol) 
were added to a solution of GOx (14.6 mg, 70 nmol) in Na2HPO4 buffer (0.05 M, pH = 8.2, 7.3 
mL), and the resulting mixture was incubated overnight in a 4 °C cold room with gentle rotation. 
The resulting Cy7-GOx-Tz conjugate was purified by passing through a ZebaTM spin desalting 
column (2 ml, MWCO 7k, Pierce) 2 – 3 times to remove excess small molecules. The 
concentration of Cy7-GOx-Tz was determined by Size Exclusion Chromatography (SEC) at 
280nm. The retention time of Cy7-GOx-Tz under a flow rate of 0.6 mL/min was 17 min. The 
number of attached Tz group per GOx was determined by titration of Cy7-GOx-Tz with the 
fluorescent dye TCO-Cy5, which has the maximum absorbance at the wavelength of 650nm, and 
does not overlap with the spectrum of Cy7. 
2.2.6 Preparation of SPION-TCO 
Since the acylation of primary amines is favored at pH 7 – 9, in order to achieve high 
conjugating efficiency, SPION particles dispersed in PBS were firstly exchanged into Na2HPO4 
buffer (0.05 M, pH = 8.2, 4.0 mL) by a ZebaTM spin desalting column (5 ml, MWCO 7k, Pierce). 
Then TCO-(PEG)4-NHS ester (1.5 mg, 3.0 µmol)  was added into the solution of the SPION (28 
mg) and incubated overnight in the 4 °C cold room with gentle rotation. To lower the possibility 
of particle aggregation, the resulting SPION-TCO were purified using Slide-A-Lyzer™ Dialysis 
Cassettes (MWCO 10k, 0.5 – 3 ml, Pierce) to remove unreacted small molecules. The SPION-
TCO conjugate was dialyzed in 1X PBS buffer 1h, 2h at room temperature, and overnight in the 
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4 °C cold room. Finally the conjugate was collected from the cassette and concentrated with 
Millipore® Amicon® Ultra-4 Centifugal Filter Concentrators (NMWL 30k). 20 mg of the 
purified SPION-Tz was obtianed in 4.0 mL 1X DPBS. The number of TCO group per SPION 
was determined by titration with the fluorescent dye Tz-Cy5, accordingly, in the SEC at the 
wavelength of 650 nm. The retention time of SPION-TCO under a flow rate of 0.6 mL/min was 
10 min. 
2.2.7 Preparation of SPION-GOx bioconjugates 
The above SPION-TCO (20 mg in 4 mL 1X DPBS) were mixed with the prepared Cy7-GOx-Tz 
(2.0 mg in 1 mL 1X DPBS), and the resulting reaction mixture was incubated 1h at room 
temperature with gentle rotation. The resulting SPION-GOx were injected into the SEC to 
confirm the conjugation efficiency. No peak of the Cy7-GOx-Tz at 750 nm would be observed if 
the bioorthogonal linkage between GOx and SPION was complete. 15 mg of purified GOx-
SPION was obtianed in 3.0 mL 1X DPBS. The amount of immobilized GOx protein was 
estimated to be 45 µg/mL based on the Bradford protein assay. 
2.2.8 Determination of hydrodynamic diameters of SPION-GOx bioconjugates using 
Dynamic Light Scattering (DLS) 
Since the SPION-GOx bioconjugates are dispensed in PBS buffer when injected intravascularly 
into mice, the hydrodynamic diameter is an important parameter that needs to be measured and 
taken into consideration to ensure that no particles are with the size over 200 nm, nor 
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aggregation are present in the injection solution. The sizes and size distributions of the SPION, 
GOx, and the SPION-GOx were determined by DLS (dynamic light scattering) technique with a 
Zetasizer Nano ZS (Malvern Instruments, Massachusetts). Samples of 0.1mg SPION-GOx, 
SPION-TCO, GOx in 600 µL PBS buffer were prepared and pipetted into cuvettes that have 
a light path of 10 mm. A refractive index of 2.45 as that of Fe3O4 was obtained from the 
handbook[135] and used for SPION-TCO and SPION-GOx samples, while a default 
refractive index of protein was used in the measurement of GOx. 
2.2.9 TMB based ROS assay 
20 μL SPION (5.0 mg/mL), GOx (1.0 mg/mL), mixture of GOx (0.5 mg/mL) and SPION (2.5 
mg/ML) without conjugation, GOx-SPION (5.0 mg/mL), and cetuximab-GOx-SPION (5.0 
mg/mL) was added into 380 μl reaction buffer (0.1 M NaAc, pH 4, 50 μg TMB), followed by 
addition of either 100 µL of 100 mM glucose or 100 µL of DiH2O.  After the mixtures were 
incubated at 37 °C for 6 h on the shaker, the absorbance was scanned and measured from 800 nm 
to 200 nm using Cary Bio 100 UV-Vis spectrophotometer. 
2.2.10 Cell Culture 
4T1 cancer cells were purchased from ATCC. They were cultured in the RPMI-1640 medium 
containing 10% FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in a 
humidified atmosphere containing 5% CO2 and 95% air. They were subcultured every 2 – 3 days 
with 0.25% trypsin-0.53mM EDTA solution at a subcultivation ratio of 1:5. 
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2.2.11 In vitro cytotoxicity evaluation of SPION-GOx bioconjugates 
4T1 cells were seeded into a 96-well plate at a density of 104 per well and cultured at 37°C for 
24h. 50 µL SPION (10 µg/mL), GOx (0.0688 µg/mL), mixture of GOx (0.0688 µg/mL) and 
SPION (10 µg/mL) without conjugation, SPION-GOx (10 µg/mL), or PBS (as control) was 
added to each well respectively, followed by addition of 100 µL of Dulbecco's Modified Eagle's 
medium (DMEM) containing 4 g/L glucose. After incubation for various time periods, the old 
DMEM medium was removed and the cells were washed with PBS 3 times. Cell viability was 
measured by using CellTiter-Glo viability assay kit. Basically, 100 µL CellTiter-Glo reagent was 
added to each well that contained 100 µL fresh DMEM. Control wells with medium but no cells 
were prepared for background luminescence. The contents were mixed on an orbital shaker for 2 
min to induce cell lysis and incubated at room temperature for 10 min to stabilize the 
luminescence signal. 
2.2.12 In vitro assessment of glucose for 4T1 cells proliferation 
4T1 cells were seeded into a 96-well plate at a density of 104 per well and cultured at 37°C for 
24h. To study the cytotoxic effects as the function of the concentration of cetuximab-GOx-
SPION and glucose, 50 µL cetuximab-GOx-SPION at various concentrations was added to a 96-
well plate seeded with A431 cancer cells, followed by addition of 100 µL of DMEM that 
contains different concentrations of glucose (4 and 20 g/L). After 1.5 h incubation, the cells were 
washed with PBS 3 times and then cultured in 200 µL of DMEM. After being incubated for 
another 12 h, cell viability was measured by using CellTiter-Glo viability assay kit. 
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2.2.13 In vivo cytotoxicity evaluation of SPION-GOx bioconjugates 
Healthy female Balb/c mice (~20g) were obtained and raised under a National Institutes of 
Health Animal Care and Use Committee (NIHACUC) approved protocol. 16 mice were 
randomly divided into 8 groups, administered with a single dose of 5 mg/mL SPION-GOx in 
PBS at a dosage of 1, 2, 3, 4, 5, 7.5, 10, 12.5 mg/kg mouse via tail vein injection. 2 other mice 
were used as control with 200 µL saline administrated at the same time point. The Size and size 
distribution of SPION-GOx bioconjugates were determined using DLS before injection to ensure 
the conjugation was complete. Meanwhile, a sample from the SPION-GOx PBS solution to be 
used on animal study was also taken to run a TMB assay, in order to verify the effective 
generation of ROS. The weights and health situation of mice were monitored every day. 
2.2.14 In vivo therapeutic efficacy of SPION-GOx on female Balb/c mice 
4T1 cells (2×105 cell/mouse) were implanted subcutaneously into the right shoulders of female 
balb/c nude mice (~20 g). In vivo therapy experiments were performed when the tumor reached 
6~8 mm in average diameter (10 days after implant). 3-5 mice were randomly assigned to 4 
groups, including Group A: SPION-GOx, Group B: SPION and GOx mixture (not conjugated), 
Group C: GOx and Group D: blank group where only saline was injected as control. Group A 
were administered with a single dose of 5 mg/mL SPION-GOx in saline at a dosage of 5 mg/kg 
mouse via tail vein injection. Group B were injected with the mixture of unconjugated SPION 
and GOx at the dosage of 5 mg/kg and 8.5 nmol/kg mouse respectively. Group C received the 
8.5 nmol GOx/kg mouse, while Group D were administrated with 200 µL saline as control. All 
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the administration was made around the same time of the day. The size and size distribution of 
SPION-GOx bioconjugates were determined using DLS before injection to ensure the 
conjugation was complete. Meanwhile, a sample from the SPION-GOx PBS solution to be used 
on animal study was also taken to run a TMB assay, in order to verify the effective generation of 
ROS. The weights and health situation of mice were monitored every day. The mice were 
anesthetized and dissected in 21 days of post-injection. 
2.2.15 Biodistribution of SPION, GOx, and SPION-GOx bioconjugates 
Healthy female Balb/c mice (~20g) were obtained and raised under a National Institutes of 
Health Animal Care and Use Committee (NIHACUC) approved protocol. The mice were 
intravenously administered with a single dose of SPION-Cy5.5 in PBS (5 mg/kg) via tail vein 
injection. Several other mice were used as control. The mice were anesthetized and dissected in 
14 days of post-injection. The major organs (heart, liver, spleen, lung, kidney, pancreas) were 
dissected. 
2.2.16 Evaluation of mice survival 
All experiments with live animals were performed in accordance with a protocol approved by the 
National Institutes of Health Committee (NIHCC). Briefly, the mice were euthanized when 
either the tumor size reaches 1.5 cm or 21 days after treatment, whichever comes first. Therefore, 
the mice survival was calculated based on the life span from the date when the mice received 
treatment to the date when the tumor size reached 1.5 cm. For each group subjected to the 
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corresponding treatment, the survival rate was calculated by dividing the number of surviving 
mice at different days of post-treatment by the total number of mice before treatment in that 
group. A survival curve was then plotted. 
2.3 RESULTS 
2.3.1 Characterization of SPION 
The SPION was synthesized through a high-temperature solution phase reaction of iron (III) 
acetylacetonate with 1, 2-hexadecanediol in the presence of oleic acid and oleylamine[136]. 
Then the amine groups were coated onto the as-synthesized SPION by ligand exchange with 
aminosilane to produce SPION-NH2. The amount of amine groups on the surface of each SPION 
was estimated to be around ~200 based on a fluorescein quantification assay. Figure 10 shows a 
transmission electron microscopy (TEM) image of the SPIONs. The particles were uniform and 
have an average size of 8 nm. Figure 11 shows the SPION was successfully dispersed in aqueous 
solution after the modification with the lipid. The suspension was stable at 4°C for more than 6 
months. 
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Figure 10. TEM image of SPION. 
 
 
 
 
Figure 11. SPION before and after ligand exchange. a, as-synthesized SPION dispersible in hexane 
(upper). b, SPION-NH2 dispersible in water (lower) after exchanging the ligand with amine groups. 
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2.3.2 Determination of SPION-GOx bioconjugates’ hydrodynamic size and size 
distribution 
Dynamic light scattering is a common physical method to measure molecule size and distribution 
in suspensions. A monochromatic light source, usually a laser, is shot into the sample. The 
principle of DLS is that when the light hits the molecules (smaller than 250 nm) in the solution, 
it gets diffracted in all directions, i.e., Rayleigh scattering. The scattering intensity fluctuates 
over time because the small molecule undergoes Brownian motion. Then the scattered lights 
from different molecules interfere with each other constructively or destructively, which also 
contributes to the information of time scale of scatters’ movement. The dynamic information of 
the particles is then derived from an autocorrelation of the intensity trace recorded. The second 
order autocorrelation curve is generated from the intensity trace: 
 
where g2(q;τ) is the autocorrelation function at a particular wave vector, q, and delay time, τ, and 
I is the intensity. The angular brackets < > denote the expected value operator. The Siegert 
equation[137] relates the second-order autocorrelation function with the first-order 
autocorrelation function g1(q;τ) as follows: 
 
where the parameter β is a correction factor that depends on the geometry and alignment of the 
laser beam in the light scattering setup. Cumulant method is a common mathematics approach 
and also the method used in the Malvern software to derive information from the first-order 
autocorrelation function: 
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, with 
 
where Γ is the average decay rate, μ2/Γ2 is the second order polydispersity index (PDI) which 
indicates the variance. The z-averaged translational diffusion coefficient Dz is derived at a single 
angle or at a range of angles depending on the wave vector q. λ is the incident laser wavelength, 
n0 is the refractive index of the sample and θ is angle at which the detector is located with respect 
to the sample cell. Parameters beyond µ3 should barely be used, because overfitting data with too 
many parameters in a power-series expansion will make all the parameters less precise[138]. 
Three types of distributions are commonly encountered when particle size distribution needs to 
be characterized. The number distribution shows the number of particles in the different size 
bins. The intensity distribution describes how much light is scattered by the particles in the 
different size bins. The volume distribution shows the total volume of particles in the different 
size bins. For isotropic particles, the scattering intensity from a spherical particle is proportional 
to the size to the sixth power. Intensity distributions emphasize the larger particles in the 
distribution, whereas the number distributions emphasize the smaller particles in the distribution. 
However, it is important to know that both are just different representations of the same physical 
reality of a distribution of different sizes. 
Therefore, the size distributions both by number and intensity of SPION and SPION-
GOx are shown in Figure 12-15 to provide more detailed information on the size and size 
distribution changes before and after the SPION-GOx bioconjugates being formed. The Z-
average diameter and polydispersity index (PDI) characterizing the size distribution are 
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summarized in Table 1. Basically, the Z-average size of SPION is approximately 62.74 nm, 
while the SPION-GOx bioconjugates are 76.53 nm. The 14 nm in size difference is the exact size 
of the globular protein GOx, indicating the successful conjugation formed between SPION and 
GOx. 
 
 
 
Figure 12. Size distribution by number of SPION. 
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Figure 13. Size distribution by intensity of SPION. 
 
 
 
 
Figure 14. Size distribution by number of SPION-GOx. 
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Figure 15. Size distribution by intensity of SPION-GOx. 
 
Table 1. Summary of DLS results 
Particles Z-average (avg ± sd) /nm PDI 
SPION-GOx 76.53 ± 1.18 0.169 ± 0.0095 
SPION 62.74 ± 1.28 0.151 ± 0.019 
 
 
2.3.3 Determination of ROS generation by TMB assay 
Formation of ROS from the SPION-GOx bioconjugates was visualized by using a chromogenic 
substrate 3, 3’, 5, 5’-tetramethylbenzidine (TMB). It produces a blue color when highly active 
ROS is present in the solution so that it can be detected at the wavelength of 650 nm using a UV-
Spectroscopy [139-141]. In the in vitro study, we used an antibody, Cetuximab, instead of the 
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peptide RGD as targeting probe, to characterize the levels of ROS produced by GOx and SPION 
alone, mixture of GOx and SPION with no conjugation, as well as GOx-SPION, and Cetuximab-
GOx-SPION. The result is presented in Figure 16, in which the peak appears at 650 nm on the 
UV-vis spectroscopy indicating the existence of ROS in the system. The result shows that 
presence of glucose, as a substrate, in the system is essential for producing ROS. Moreover, it 
suggests that neither GOx nor SPION alone is able to produce highly active ROS from glucose.  
It is interesting that even a mixture of unconjugated GOx and SPION cannot generate ROS. This 
result suggests that synergistic activity between GOx and SPION plays a key role in the process 
of ROS, where GOx generates hydrogen peroxide from glucose and SPION catalyzes the 
production of ROS from hydrogen peroxide. If GOx and SPION are not in a close distance as in 
the case of Cetuximab-GOx-SPION bioconjugates, the intermediate hydrogen peroxide may 
react with other chemicals in the system very quickly before it reaches SPION to generate ROS. 
The result in Figure 17 also shows that Cetuximab does not significantly change the activity of 
SPION-GOx in producing ROS. Figure 18 shows the change of ROS concentration in the 
solution as a function of time. The level of ROS in this system keeps increasing till 1 h after the 
reaction starts. After incubated at 40°C overnight, the blue color of the solution faded and some 
precipitation and aggregation of SPION-GOx were observed. 
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Figure 16. TMB assay absorption spectra produced by: GOx, SPION, mixture of GOx and SPION without 
conjugation, GOx-SPION, and Cetuximab-GOx-SPION, with and without the presence of glucose. 
 
 
 
 
Figure 17. TMB assay absorption as results of different incubation SPION-GOx. 
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2.3.4 Cytotoxicity of SPION-GOx bioconjugates in vitro and in vivo 
4T1 murine breast cancer cell line was used to demonstrate the tumor cell destructive capability 
of the SPION-GOx-RGD bioconjugates. 4T1 cells were incubated with SPION-GOx-RGD, 
SPION-GOx and other parallel treatments, including SPION with no conjugation, GOx, mixture 
of unconjugated SPION and GOx under the same condition. Cell viabilities after different 
treatments are shown in Figure 18, where 1X PBS buffer is used as negative control (assuming 
100% viability, not shown in the chart). Treatment with 10 μg/mL SPION-GOx-RGD and 
SPION-GOx resulted in comparable cell viabilities after 24 h, that is, nearly no cells survived. In 
contrast, no significant reduction in the cell viability was observed in the groups where cells 
were treated with either SPION alone or the mixture of unconjugated SPION and GOx after up 
to 24 h in the presence of glucose with the same concentration (4 g/L). 
 
 
 
Figure 18. Cell viability 1 h, 3 h, 4 h, 24 h after treatment with mixture of unconjugated SPION and GOx; 
SPION only; GOx only; SPION-GOx; SPION-GOx-RGD. 
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Figure 19. Cell viability 3.5 h after treatment with SPION-GOx-RGD and 4 g/L glucose. 
 
We also studied the cytotoxicity of the system as a function of the concentration of 
SPION-GOx-RGD. Figure 19 presents cell viabilities after 3.5 h treatment with SPION-GOx-
RGD at 4 different concentrations (0.01, 0.1, 1, and 10 μg/mL) in the presence of 4 g/L glucose. 
The cell viability decreases as the concentration of SPION-GOx-RGD increases.  
Moreover, from the cytotoxicity evaluation of SPION-GOx bioconjugates on female 
balb/c mice, we found that the mice only could not last for more than 48 hours after the 
administration at the dosages of 10, 7.5, 6 mg/kg mouse. However, at a slightly lower 
concentration of 5 mg/kg mouse, the mice were able to survive despite experiencing a slight 
weight loss of approximately 2 g. It should be noted that the cytotoxicity study was performed on 
healthy mice that were not implanted with any tumor. Knowing that the SPION-GOx 
bioconjugates will passively accumulate at the tumor site, which has been confirmed in the 
biodistribution study, we hypothesized the 5 mg/kg would be a reasonable dose for the next step 
therapeutic efficacy study because the accumulation of the bioconjugates in other organs like 
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liver and kidney, would be less severe. That is to say, even though the tumor bearing mice are 
less healthy than normal mice, they may be more tolerant to SPION-GOx bioconjugates. The 
targeting peptide RGD was not conjugated to the SPION-GOx because we understood from the 
optical imaging and PEG biodistribution results that SPION-GOx were able to accumulate 
passively at tumor without the guidance of targeting agent because of the EPR effect. Moreover, 
a shift in project goal happened since originally, we were going to study a two-step cancer cell 
destruction with injecting RGD-GOx and SPION separately and let them assemble at tumor to 
release ROS, in order to minimize the cytotoxicity that might arise in the early stage after 
injection. Again, though this project was done within a tight schedule and limited resource, we 
still got to the same conclusion that SPION-GOx can generate the destructive ROS that causes 
cancer cell death. 
2.3.5 Biodistribution of SPION-GOx determined by optical imaging 
A preliminary animal study was also conducted to determine the biodistribution of SPION in 
mice. It was realized by detecting the fluorescence signals emitted by the Cyanine7 labeled 
SPION in the organs of interest. Animal experiments were conducted in accordance with the 
guidelines for the Care and Use of Laboratory Animals of the Medical Research Council of 
University of Pittsburgh. Optical imaging was performed with a Xenogen IVIS Spectrum 
imaging system (IVIS Lumina XR; excitation, 745 nm; emission, 780 nm; exposure time, 1 s; 
binning, medium; field of view, C). Imaging and quantification of signals were controlled by the 
acquisition and analysis software, i.e., Living Image 2.5 software (Xenogen, Alameda, 
California). Injections of SPION-Cy7 with tumor-bearing mice were performed 14 days after the 
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implantation of tumor cells. Each mouse was injected with 5mg Fe/kg mouse (dissolved in 200-
μL saline) via the tail vein when they were anesthetized by continuous exposure to 2.5% 
isoflurane. Mice were sacrificed and images at the following time points were collected: 3-, 4-, 
5-, 6-, and 7 days post-injection. The main normal organs, such as lung, heart, blood, liver, 
pancreas, spleen, kidney, stomach and intestine, muscle and bone, as well as the tumor were 
harvested for in vitro imaging. 
It was observed from Figure 20 that SPION had accumulated on the tumor site on the 
third day after injection. This passive accumulation is due to the enhanced permeability and 
retention (EPR) effect, which is a property of nanoparticles with ultra-small sizes tending to 
accumulate in tumor tissue much more than they do in normal tissues. Biodistribution of SPION 
concentrations in various organs, in the rank order of magnitude, was liver > kidney > pancreas> 
other. This result shows that SPION mainly accumulates in the liver. The concentration 
difference in the distribution results from the SPION metabolism. 
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Figure 20. Biodistribution of SPION-Cy7. 3-, 4-, 5-, 6-, 7 days post injection. From upper to lower, left to 
right: lung, heart, blood, liver, pancreas, spleen, tumor, kidney, stomach and intestine, muscle and bone. 
 
2.3.6 In vivo therapeutic efficacy of SPION-GOx on female Balb/c mice 
By measuring tumor sizes and weight after treatment, we can evaluate the therapeutic effect of 
SPION-GOx bioconjugates on 4T1 cancer cells in animals. Shrinking tumors are promising signs 
indicating the effectiveness of the ROS introduced from SPION-GOx bioconjugates on cell 
destruction, while no severe toxicity effect like significant weight loss or animal death should be 
observed. The normalized tumor sizes since the day of mice receiving treatment after tumor 
implantation in each treatment group are shown in Figure 21. 
A great slowdown of tumor growth is observed in the mice treated with SPION-GOx 
(red) as compared to the all 3 control groups, which agrees with the cell study results that the 
ROS generated from the conjugated SPION-GOx could effectively destruct cancer cells. The 
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mice in this group experienced a weight loss of ~2g in the first 4 days but grew back to their 
normal weights before treatment and kept constant soon after the drop. Unconjugated SPION and 
GOx (blue), and GOx alone (yellow) both stimulated the tumor growth in the 21-day span, which 
can be explained by the double role that ROS play to cause cell proliferation when a slight 
increase in ROS level is introduced. While SPION and GOx mixture yield a steady tumor 
growth, treatment with GOx at a concentration of 8.5 nmol/kg mouse created an explosion. One 
mouse in saline group had very fast-growing tumor that yields the outlier in that group and 
contributes to a large standard deviation on Day 10. It was sacrificed at day 12, leading to a 
decrease of average tumor size growth rate in the group. 
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Figure 21. Therapeutic efficacy of the SPION-GOx bioconjugates. 3-5 female balb/c mice bearing 4T1 
tumor cells were assigned to each group. The 4 groups were administrated at Day 0 with: unconjugated SPION and 
GOx (blue), GOx (yellow), saline (green) and SPION-GOx (red), respectively. All mice were sacrificed at Day 21 
after tumor size and weight measurement. 
 
2.3.7 Survival curve 
The survival curve indicating the living status of the animals is shown in Figure 22. All the 
decreases in animal number were related to sacrifice due to the outgrowing tumor. No animal 
died from any type of treatment (SPION-GOx and three control groups, including GOx, 
unconjugated SPION and GOx mixture and saline) in the 21-day study. Additionally, the 
SPION-GOx bioconjugates slowed down the tumor growth dramatically so that there were no 
mice sacrificed until the end point of the in vivo study. However, due to a limited number of 
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animals used in each group, the death of one mouse affects the survival curve result 
tremendously. 
 
 
 
Figure 22. Survival curve. 
 
2.4 DISCUSSION 
It is evident that SPION-GOx bioconjugates are able to destruct tumor cells both in vitro and in 
vivo via in situ production of ROS. This low side effect treatment can be a promising strategy for 
cancer therapy. 
Uniform and ultra-small size iron oxide nanoparticles were essential for the 
bioconjugates to effectively accumulate at tumor through EPR effect. Therefore, the thermo 
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decomposition method was chosen to meet the specific size requirements. The as-synthesized 
nanoparticles were characterized by transmission electron microscopy (TEM) that shows the 
Fe3O4 core and later using dynamic light scattering (DLS) that represents the hydrodynamic 
diameter and size distribution when the nanoparticles were functionalized with the PEG chain to 
be dispersible in aqueous solution. The thickness of the coating layer from the DSPE-PEG2000-
NH2 in aqueous solutions can be estimated with a scaling model, which was originally developed 
by Johnsson et al[142]. Briefly, the thickness of PEG layer is determined by the following 
factors: the number of monomeric units per PEG chain, the statistical length of a monomer (= 
0.39 nm), the number of PEG chains on the surface, and the radius of the core. It should be noted 
that both Fe3O4 core and the lipid bilayer formed by DSPE and oleic acid/oleylamine contribute 
to the radius of the core. The lipid bilayer is usually assumed to be the same size of cell 
membrane (~ 3 nm). The experimental measurements from TEM and DLS agree with theoretical 
predictions. After the particles were prepared and stabilized, the functionalization of SPION and 
GOx using click chemistry was performed following a similar procedure. The key step to modify 
SPION and GOx with the NHS esters is to adjust the pH to 8-9. This is because hydrolysis is a 
competing reaction with primary amines of proteins/peptides. Acylation is favored using 
concentrated protein solutions (1 - 5 mg/ml) at pH 7 - 9. It is also important to use an amine-free 
buffer for the NHS ester reactions. Buffers containing primary amines (e.g. Tris, Glycine) would 
result in a loss of available NHS esters for the main reactions. NHS esters are moisture-sensitive 
and readily hydrolyze, so that they need to be dissolved in a dry water-miscible organic solvent 
such as DMSO or DMF prior to use. 
Secondly, the single peak from UV-vis FPLC as well as Z-average particle size from 
DLS indicated that the click chemistry is an effective method for conjugation of iron oxide 
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nanoparticles with another large biomolecule, GOx. This is an important progress in the work 
because the conjugated product is the foundation of the successful generation of ROS and the 
prerequisite of the delivery to tumor site without a targeting agency attached. It was one of the 
most challenging preparation steps due to the intrinsic inconsistency of nanoparticles and the 
batch-to-batch difference because amine functionalized SPION were purchased from 
OceanNanotech for further modification with TCO-PEG4-NHS esters because of the limited 
time. 
The in vivo cytotoxicity evaluation result shows that the mice could tolerate the SPION-
GOx at 5.0 mg/kg mouse from a single injection. From the biodistribution obtained from optical 
imaging, we observed the significant accumulation of SPION-GOx in the tumor, while as time 
goes by, the residues in other major organs, like liver, kidney, and pancreas were slowly cleared. 
This result suggests that the SPION-GOx can remain at the tumor site generating ROS as a long 
lasting therapeutic cancer drug, which is convenient for patients since frequent repeating 
injections are avoided. Due to the limited resources, in the cytotoxicity assessment, each dose 
was administrated on only 2-3 mice. This could possibly result in a “pseudo positive” conclusion 
because of the lack of statistical analysis from multiple data points, which can be resolved by an 
experimental design with a greater number of animals assigned in each group, and a 
comprehensive animal study with complete demonstration with all positive and negative control 
groups. 
The key experiment to test the production of ROS from the SPION-GOx system is using 
the TMB assay. The TMB assay results of the peaks at 650 nm on the UV-vis spectroscopy 
indicated the existence of ROS in the system. In addition, the result showed that neither GOx nor 
SPION alone is able to produce highly active ROS from glucose, which is the substrate that is 
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essential for production of ROS. It is noticeable that a mixture of unconjugated GOx and SPION 
does not generate as much ROS as the conjugated SPION-GOx does. This result suggests that 
synergistic activity between GOx and SPION plays a key role in the process of ROS, where GOx 
generates hydrogen peroxide from glucose and SPION catalyzes the production of ROS from 
hydrogen peroxide. If GOx and SPION are not in a close enough distance as in the case of 
SPION-GOx bioconjugates, the intermediate hydrogen peroxide may react with other chemical 
species in the system quickly before it reaches SPION to generate ROS. Another significant 
result of our experiment is that mass production of ROS and destruction of cells only takes place 
when SPION and GOx are conjugated. This sheds new lights to an alternative therapy with 
unprecedented low-side effect and specificity by first delivering the SPION to specific tumor and 
then introducing the targeting agent modified GOx to initiate the ROS production. 
Distinguishable from other ROS-mediated therapies, our platform only requires blood glucose as 
the reactant for the production of ROS, and it turns a nutrient required for tumor proliferation 
into a cytotoxin that destroys the tumor cells. 
A concern with the platform is the systematic variation introduced by the nanoparticles. 
Some inconsistency exists from batch to batch, which sometimes leads to inexplicable results. 
For example, when we were coupling the TCO-PEG4-NHS onto the SPION surface, using the 
reaction condition, we got very different TCO per SPION results from different batches of 
nanoparticles. Therefore, repeatability is an issue that needs to be taken into consideration to 
make any rigorous conclusion. 
Overall, our study demonstrates that SPION-GOx bioconjugates is a promising approach 
for cancer therapy with low side effect in normal tissues but long lasting targeted cancer cell 
destruction capability. Additionally, with the intrinsic MRI guidance ability, SPION-GOx 
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delivery process can be guided and confirmed by MRI, which lays the ground for imaging-
guided drug delivery and potentially a theranostic (combination of diagnostics and therapy) 
platform. 
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3.0  MULTISTAGE SEPARATION OF CELLS USING HYDROPHOBIC 
INTERACTIONS ENABLED BY TEMPERATURE RESPONSIVE POLYMER 
3.1 INTRODUCTION 
Despite of the advanced techniques in surgery, metastasis is still one of the most critical 
problems that affect the prognosis of cancer patients[114]. During metastasis, tumor cells are 
detached from the original site and shed into the bloodstream, then arrested in the small vessels. 
These so called circulating tumor cells (CTCs) can finally grow into secondary tumors after they 
successfully survived the host defense mechanisms and established a microenvironment. In other 
words, CTCs are the seeds for subsequent growth of additional tumors in fairly distant organs, 
resulting in the majority of cancer-related deaths. 
It is clinically important to find out a way that a small quantity of CTCs can be detected 
in the relatively large amount of blood sample. In previous studies, disseminated tumor cells in 
peripheral and mesenteric venous blood were detected by conventional cytology or 
immunocytological methods using monoclonal antibodies (mAbs), cytokeratin (CK) or epithelial 
cell membrane markers[115-117]. However, these staining methods are too complicated for 
routine use, and the sensitivity was limited by its low analysis capacity. Developments in 
molecular technology have made it possible to detect small numbers of tumor cells in the 
peripheral blood, and several previous reports have demonstrated the feasibility[42, 47]. 
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Magnetic assisted separation has attracted considerable attentions providing a rapid and 
simple method for efficient separation of cell population [119, 143-145].  Basically, magnetic 
particles (MNPs) bind specific cells when added to cell mixture and separate them from the 
complex heterogeneous mixture when an external magnetic field is applied. One of the highly 
efficient separation is enabled by the high binding affinity and specificity of certain receptors 
that are immobilized on the MNPs, such as monoclonal antibody (mAb), peptide, or aptamer, 
which capture cells selectively[146]. A few magnetic assisted cell sorting (MACS) technologies 
have been established recently[144, 147-149].  CellSearch is an FDA-approved isolation system 
using epithelial cell adhesion molecule (EpCAM) coated magnetic beads[13, 147, 150]. The 
ability of CellSearch to detect circulating tumor cells (CTCs) from the peripheral blood of 
patients with metastatic breast cancer was validated by Riethdorf et al[151], who found that 
CTCs were detected in ∼70% of metastatic breast cancer patients (n = 97) using 
CellSearch[151]. Alternatively, Hoshino et al. used a flat dimension microfluidic channel 
combined with high gradient magnetic field to capture magnetically tagged CTCs[149]. They 
achieved a 90% capture rate at a flow rate of 10 ml h-1, with 25% fewer particles being required 
in comparison to CellSearch[149]. 
However, a major obstacle that hinders the MACS from achieving adequate separation 
efficiencies is non-specific interactions between cells and MNPs. For instance, epithelial-specific 
antibodies can label not only non-tumor epithelial cells by specific labelling, but also non-tumor 
non-epithelial cells by non-specific labelling, thus giving false positive results[152].When very 
large separation efficiencies are required, problems caused by the non-specific interactions 
become significant and challenging[153, 154]. 
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Herein, we report a multistage cell separation platform to circumvent the challenge 
resulting from non-specific interactions in current single-stage magnetic separation, shown in 
Figure 23. In this platform, we utilized poly(N-isopropylacrylamide) (pNIPAM) which has been 
applied in protein purification[155-157] and cell separation[158-160], as it undergoes a unique 
reversible phase transition at its lower critical solution temperature (LCST) of ~32°C[161]. By 
manipulating the hydrophilic-to-hydrophobic phase transition of the polymers simply through 
temperature cycling, we were able to reversibly capture and release target cells when pNIPAM 
was grafted onto both MNPs and target cells. In this work, A431 and HeLa cell lines were used 
as target and non-target cells, respectively, for their significant difference in  epidermal growth 
factor receptor (EGFR) expression level[162], while Cetuximab (C225) was the mAb used to 
bind to EGF receptor at a high binding affinity (Kd = 0.39 nM)[163]. Flow cytometry was 
utilized in the analysis of cell counting. The results showed an increasing enrichment factor after 
multiple separation cycles, which indicates that A431 cells (target) can be effectively separated 
from HeLa cells (non-target) using the multistage platform and that the separation efficiency 
increases with the number of separation cycle. 
The key approach to the multistage separation is based on reversible hydrophobic-to-
hydrophilic transition of the polymers tethered to the magnetic particles (MNPs) and target cells 
by changing the temperature. Zhu et al has utilized temperature change in their microfluidic 
separation device to release the captured CCRF-CEM cells from DNA aptamer sgc8c by raising 
the temperature to 48°C [164]. In order to provide a mild environment for cells, among various 
temperature-responsive polymers that undergo a reversible phase transition in aqueous solutions 
upon changing of the temperature [7-11], poly(N-isopropylacrylamide) (pNIPAM) is chosen in 
this work. PNIPAM exhibits a well-known temperature-responsive phase transition in aqueous 
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solution at its LCST of about 32°C [12,13]. It is hydrophilic and water-soluble when the 
temperature is below LCST but becomes hydrophobic and aggregate in aqueous solutions when 
the temperature is above LCST. The aggregation can be dissolved in aqueous solutions when the 
temperature is decreased to below LCST again. This reversible hydrophilic-to-hydrophobic 
transition is believed to be accompanied by a conformational change of the polymer chain from a 
disordered, random hydrophilic coil to an ordered, collapsed hydrophobic globule.  By attaching 
pNIPAM to both target cells and MNPs, target cells can be captured and released by the MNPs at 
a higher efficiency than the non-target cells, which may also be captured and released by the 
MNPs due to non-specific interactions. The difference in the capture-and-release efficiencies of 
target cells versus non-target cells in a single cycle will be amplified by multiple separation 
stages, following a similar concept of the distillation process. Therefore, the overall separation 
efficiency will increase with the number of separation stages. 
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Figure 23. Realistic process flow for multistage separation scheme. (a) Cycle starts with a mixture of target 
(T) and non-target (NT) cells; (b) PNIPAM-MNPs added; (c)Trigger pNIPAM to its hydrophobic conformation at 
37 °C, some target cells may not be captured while some non-target may get captured; (d) Attract MNPs in a 
magnetic field; (e) Disperse the pellet in fresh buffer; (f) Trigger pNIPAM to hydrophilic phase by cooling the 
mixture to 4°C, some target may still be attached on MNPs, and some non-target may escape; (g) Separate the 
MNPs in a magnetic field, the pellet may contain some target while the supernatant may have some non-target; (h) 
Cycle ends with target-rich in the supernatant but not a complete separation of target from non-target cells. 
 
To tether pNIPAM to MNPs, poly(acrylic acid)-modified Fe3O4 magnetic particles (PAA-
MNPs) were synthesized in a solvothermal method and amino-terminated pNIPAM was 
covalently attached to the MNPs via coupling the amine group with the carboxyl groups. On the 
other side, to selectively attach pNIPAM to target cells, we first conjugated pNIPAM to protein 
A, which is a secondary antibody that binds the Fc region of immunoglobulin G (IgG) from 
many mammalian species with a high specific binding affinity[165]. Carboxylic acid terminated 
pNIPAM (pNIPAM-COOH) was used to react with protein A to form stable amide linkages. 
Therefore, when the pNIPAM-protein A is mixed with the targeting mAb Cetuximab, the 
resulting pNIPAM-protein A-Cetuximab complex can selectively capture the cells that 
overexpress EGFR. It has been reported that the LCST of pNIPAM conjugated to protein A 
through this approach does not change significantly after the conjugation[166]. Cetuximab is 
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previously labeled with fluorescence dye to distinguish target cells from non-target cells in the 
cell mixtures for the subsequent flow cytometry analysis. 
After the preparation of pNIPAM tethered MNPs and pNIPAM-protein A-Cetuximab 
complex, the separation process starts with adding pNIPAM-MNPs to the cell mixtures 
containing both the target and the non-target cells. Subsequently, the cell mixture is incubated up 
to 37 °C for 10 min in the dark. The aggregates are then collected by a neodymium−iron-boron 
magnet attached to the wall of vials. The magnetically collected cell pellet is separated from the 
bulk solution by removing the supernatant. After the cell pellet is redispersed in the cold PBS 
buffer, the resulting cell suspension is incubated at 37 °C again and ready to be captured by the 
MNPs. After multiple capture-and-release cycles described above, the overall or enrichment 
factor is therefore amplified to achieve a high separation efficiency. 
3.2 METHODS 
3.2.1 Synthesis of MNP 
The PAA-MNPs were synthesized using the solvothermal method. Briefly, FeCl3 (0.8 g) was 
dissolved in ethylene glycol (40 mL) with vigorous stirring, followed by addition of NaOAc (3.6 
g) and PAA (1.0 g). The mixture was stirred continuously for 30 min, sealed in a Teflon-lined 
stainless-steel autoclave, and then reacted at 200 °C for 10 h. After the reaction, the autoclave 
was cooled to room temperature. The products were collected, washed several times with 
ethanol, and then dried under a vacuum at 60 °C before characterization and usage. 
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3.2.2 Characterization of MNP 
The size and morphology of the as-synthesized PAA-MNPs were characterized using scanning 
electron microscopy (SEM, Philips XL-30 field, 15 kV). The crystal structures of the PAA-
MNPs were examined by using powder X-ray diffraction (XRD) (Philips X’pert Diffractometer 
using CuKα radiation, λ=1.54178 Å). The sample of PAA-MNPs was washed five times with 
ethanol, redispersed in water and dried in a powder form. 
3.2.3 Modification of MNP with pNIPAM 
The carboxyl group on the surface of PAA-MNPs was covalently linked to the amino-terminated 
pNIPAM via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) chemistry. 
The PAA-MNPs (0.5 mL, 2.5%) were washed three times in 0.1 M carbonate buffer (pH 9.6) 
and then another three times in 0.1 M MES buffer (pH 6.5). After washing, the MNPs were 
redispersed in MES buffer. To activate the carboxyl groups, fresh solution of EDC (2%, w/v) in 
MES buffer was added and the mixture was incubated for 3 h at room temperature in the dark. 
After incubation, the MNPs were washed three times with MES buffer to remove the unreacted 
EDC. Then, the MNPs (1-fold) were redispersed in 0.1 M borate buffer (pH 8.5) and 50-fold 
amino terminated pNIPAM was added for the functionalization. The mixture was incubated 
overnight at room temperature in the dark. Following conjugation, the MNPs were magnetically 
separated and thoroughly washed with PBS (pH 7.4) to remove unbound amino-terminated 
pNIPAM. The MNPs were then rinsed thoroughly, and finally stored in storage buffer (PBS, 
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0.1% BSA w/v) with a concentration of 1 mg/mL at 4 °C. Similar procedure was used for 
grafting of carboxyl-terminated pNIPAM to Protein A. 
3.2.4 Fluorescence labeling of Cetuximab with FITC 
Saturated Sodium bicarbonate (NaHCO3) solution was firstly added to 1ml of 2mg/mL (0.013 
nmole) Cetuximab stock solution to adjust pH to 8-9. 0.063 mg (0.13 nmole) 5(6)-
Carboxyfluorescein N-hydroxysuccinimide ester dissolved in DMF was added to the Cetuximab 
solution and incubated at 37°C for 4 h. Afterwards, the excess fluorescence dye was removed by 
desalting column with a cutoff molecular weight of 7,000. The product was dissolved in PBS 
buffer (pH 7.4) and ready for use. 
3.2.5 Multiple separation enabled by reversible capture-and-release of target cells using 
pNIPAM-MNPs 
The A431 cells and HeLa cells were cultured following the ATCC cell culture procedures. After 
the cells were harvested from cell culture flasks and counted using a hemocytometer, the two 
types of cells were mixed at several ratios, including A431: HeLa = 1:1, 1:2, 1:10, 1:20. The cell 
mixtures were incubated with the protein A-pNIPAM complex at 37°C for 1 h in the dark. 
The separation process started with adding a certain amount of pNIPAM-MNPs to the 
mixtures containing both the target and the non-target cells. Subsequently, cell suspension of 1 
mL 4 °C PBS buffer was warmed up to 37 °C and then incubated for 10 min in the dark. The 
aggregates were then collected by a neodymium−iron-boron magnet attached to the wall of vials. 
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The magnetically collected cell pellets were separated by removing the supernatant and then 
redispersed in a 4 °C PBS buffer. The resulting new cell suspension was again incubated at 37 
°C for 10 min in the dark. The above capture-and-release cycle was repeated for a specified 
number of times as needed. A small amount of cell mixture sample was taken after each 
separation process for flow cytometry cell counting. 
3.2.6 Flow cytometry 
Samples from cell mixtures were counted and the numbers non-target (HeLa) and target (A431) 
in PBS buffer after each capture-and-release cycle were determined using a BD FACS Aria flow 
cytometer (BD BioSciences, San Jose, CA). 
3.3 RESULTS  
3.3.1 SEM of PAA-MNP 
To demonstrate the feasibility of the multistage cell separation scheme, we firstly performed a 
proof-of-concept experiment by using polystyrene (PS) microspheres to mimic cells. Fluorescent 
PS microspheres grafted with pNIPAM were used to mimic target cells; carboxylate non-
fluorescent PS microspheres (bare spheres with no pNIPAM on the surface) were used to mimic 
non-target cells, noted that the temperature-responsive polymer pNIPAM was covalently linked 
to the target spheres in advance. The size of the microspheres is about 5 µm, which is on the 
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same length scale as cells. Two types of PS microspheres were first mixed and then separated in 
multiple stages. 
 
 
 
Figure 24. SEM image of poly (acrylic acid) modified MNPs (PAA-MNPs). 
 
Poly(acrylic acid)-modified MNPs (PAA-MNPs) were synthesized and tethered with 
pNIPAM in a one-step solvothermal method, in which PAA acted both as a ligand and a surface 
functionalization agent. Figure 24 presents an SEM image of the resulting products. The as-
synthesized PAA-MNPs are uniform spheres of about 300 nm in diameter. The PAA-MNPs were 
well dispersed in water by sonication and the suspension remained stable for more than 0.5 h 
before precipitation started. The PAA-MNPs were attracted to where the magnet was placed and 
agglomerated at the vial wall within a few seconds, leaving the supernatant clear. After removing 
the magnet, the PAA-MNPs were easily redispersed in water with gentle shaking. These results 
indicate that the synthesized MNPs possess both a high magnetization (so that they can be 
effectively separated from solution by using a moderate magnetic field) and a superparamagnetic 
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property (so that the aggregated MNPs can be easily re-dispersed in solution upon removal of the 
magnetic field). Both properties are required for the separation proposed here. 
3.3.2 Multistage separation of A431 from HeLa cells result analysis using flow cytometry 
After the demonstration of the separation scheme with microspheres, we moved on to real tumor 
cells. The cell lines we used here were A431 and HeLa as targets and non-targets, respectively, 
with their significant difference in expression level of epidermal growth factor receptor (EGFR). 
EGFR is a membrane bound protein related to cell growth, proliferation for both healthy and 
cancerous cells. The average EGFR density on A431 cell surface was found to be 636/ μm2 with 
an estimation of 5 × 105 EGFR per cell measured by Surface Plasmon Resonance imaging 
(SPRi) technique, while HeLa were found to be 270 receptors/μm2, corresponding to 0.53 per 
cell, much lower than A431. Other than linking pNIPAM to target spheres directly, when it came 
to cells, pNIPAM were firstly conjugated to protein A and then form a complex with antibodies 
which will bind to the target cells through antibody-antigen interaction. The commercialized 
drug used in the treatment of metastatic colorectal cancer, Cetuximab (C225), which is a 
chimeric IgG1 monoclonal antibody that blocks the EGFR activation, was used in this study as 
the antibody that specifically binds to the targets surface. 
Flow cytometry data analysis is based on the principle of gating. Gates are placed around 
populations of cells with common features, usually forward scatter, side scatter and marker 
expression, to investigate the cell population. Usually, before a flow cytometry experiment, it is a 
good idea to find out much information about cell lines and include the right controls. The first 
step in gating is often distinguishing populations of cells based on their forward and side scatter 
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properties. Forward and side scatter give an estimation of the size and granularity of the cells 
respectively. Moreover, in our case, we already know that A431 cells have a known 
overexpressing marker, EGFR, it was helpful to include this information by staining the cells 
with C225 conjugated to fluorophores as it will help identify the target cells in the later analysis 
for cell mixtures. Conversely a known negative, in this case, HeLa cells with low expression of 
EGFR, can allow us to set negative gates and determine real populations. Dead cells often have a 
lower level of forward scatter and are found at the bottom left corner of the density plot. 
 
 
 
Figure 25. Gating strategies of positive control A431 cells. Top left is SSC vs FCS density plot, each dot 
on the plot represents an individual particle that has passed through the laser; top right and bottom left are FSC-W 
vs. FSC-H and SSC-H vs SSC-W respectively, which gives narrow vertical population plots; bottom right is a single 
parameter histogram to show the high expression of the EGFR marker on A431 cells stained with C225-FAM. 
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Figure 26. Gating strategies of negative control HeLa cells. Top left is SSC vs FCS density plot; top right 
and bottom left are FSC-W vs. FSC-H and SSC-H vs SSC-W respectively; bottom right is the histogram to show the 
low expression of the EGFR marker on HeLa cells incubated with C225-FAM. 
 
Providing all the positive results from the microspheres study showing the proposed 
multistage separation scheme to be effective, we conducted the experiments with the two types 
of tumor cells to verify the feasibility of our idea in terms of biologically active cells. We mixed 
target A431 with non-target HeLa at ratios of (RT/NT) of 1:1, 1:2, 1:10 and 1:20, and three 
separation cycles were conducted for each sample. The antibody C225 was labeled with a green 
fluorescein, 5 - (and-6)-Carboxyfluorescein (FAM), to create a fluorescent signal that can be 
identified by the detector during the flow cytometry analysis when it was bound to the target 
cells. We incubated the FAM-C225 with the cell mixture for 1.5h and removed the free FAM-
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antibody in the solution by centrifugation. Afterwards, the pre-prepared protein A/pNIPAM 
conjugation was added to finally attach pNIPAM to the target cell surface. 
 
 
 
Figure 27. Top two histograms are C225-FAM stained A431 and HeLa cells, respectively; bottom 
histogram is the overlay of a negative population HeLa onto the stained population A431 allows easy identification 
of the positive cells. 
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Figure 25-27 shows the gating strategy adapted by analyzing the A431 and HeLa samples 
separately, as positive and negative controls and the regimes for the green FAM signals will fall 
in at the wavelength of 488nm. 
 
 
 
Figure 28. Stacked histogram of FAM fluorescence signals in cell mixture starting at the ratios of HeLa: 
A431 at 1:1, 2:1, 10:1 and 20:1. 
 
 
 
Figure 29. Overall enrichment factor koverall vs. the number of separation cycles with various initial ratios of 
target to non-target cells. 
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The koverall calculated from each sample after three capture-and-release cycles (Figure 28) 
are shown in Figure 29. An ascendant tendency in the overall enrichment factors as the number 
of capture-and-release cycles increase is still noticeable, even though the overall enrichment 
factors of 2.65, 3.69, 1.71, 1.27 (when the initial RT/NT was 1:1, 1:2, 1:10 and 1:20 respectively) 
are not as large as those from the microspheres separation process. 
3.4 DISCUSSION 
This multistage cell separation process employs the distillation concept that is commonly used in 
oil industry for transforming crude oil into fuels. Distillation is the process of separating the 
components from a mixture by selective boiling and condensation. It may result in either nearly 
pure products or a partial separation that increases the concentration of selected components of 
the mixture. When the boiling points of the components are sufficiently close so that Raoult's 
law must be taken into consideration, successive distillations are used to separate the components 
by repeated vaporization-condensation cycles. Each vaporization-condensation cycle yields a 
purer solution of the more volatile component. Similarly, since single stage separation cycle is 
not able to achieve adequate separation efficiency as mentioned, the multistage cell separation 
platform is designed. 
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Figure 30. Schematic flow chart for multistage separation of cells. 
 
The target cell corresponds to the more volatile component in the solution as in 
distillation for its higher binding affinity to the antibody as compared to non-target. In the 
configuration shown in Figure 30, the cells of “target-rich” streams separated from each flash 
cycle are used as the feed stream in the next “higher” flash cycle. A small portion of the streams 
is collected for flow cytometry analysis. The overall enrichment factor of this repeated separation 
process is y1/z for target cells. 
The as-designed multistage separation of cells using temperature responsive pNIPAM 
was proven to be feasible by analyzing the resulting samples from each separation. The as-
synthesized PAA-MNPs were well dispersed in PBS buffer at both 4°C and 37°C until the 
multiple separation cycles were completed, which meets the prerequisites for maintaining stable 
heterogeneous cell-and-MNPs suspension. The enrichment factor for target cells shows an 
obvious tendency to increase as the number of separation cycles increases, which correlates with 
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circumvention of the non-specific interaction between MNPs and non-target cells that is 
described above. Similar to Zhu’s strategy to release the captured cells from aptamer by 
temperature change[164], the capture step here was performed at a moderate temperature of 
37°C with the hydrophobization of pNIPAM observed, which provides a gentler separation 
condition for cells as compared to 48°C. 
However, the enrichment factors following the current design are relatively low, in 
comparison to the ones from multistage microspheres separation study[167], especially 
considering that the initial target to non-target ratio is much smaller in a blood sample with very 
rare CTCs. The low koverall might be caused by a few reasons. Firstly, we observed that after the 
second and third temperature increase to 37°C, the hydrophobic pNIPAM chains that are 
attached to both cells and MNPs were tangled with each other, resulted in the precipitation of 
some cells and MNPs from the suspension, which might be related to surface charge change. 
This leads to a loss of usable magnetic beads for the following separation cycle, which are 
essential for achieving a high separation efficiency. Adding additional MNPs after each step to 
the mixture is necessary to maintain the separation efficiency. Meanwhile, some of both target 
and non-target cells are lost as well because it was difficult to aspirate the precipitation to form a 
fine suspension again. Moreover, the type of MNPs added to the mixture might also be a factor 
that can be manipulated to achieve a higher separation effiency. Due to a limited timeframe and 
resources, we only used one size of MNPs at one initial concentration in this study. The system 
could be further optimized by tuning the size of MNPs, the density of pNIPAM on MNPs, the 
amount of pNIPAM modified MNPs added to the mixture, etc. 
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4.0  OUTLOOK AND SUMMARY  
4.1 OUTLOOK 
We have demonstrated that the SPION-GOx bioconjugates system can generate ROS causing 
cell destruction in vitro, while the in vivo cytotoxicity evaluation indicated that the toxicity of the 
bioconjugates were able be maintained at a low level with a dosage of 12.5 mg/kg mouse. The 
therapeutic efficacy of the designed system still needs to be evaluated on animal models. 
Meanwhile, more control groups should also be studied in the future research, including SPION 
only, GOx only, mixture of unconjugated SPION and GOx, and blank group (saline). The 
biodistribution determined from previous study was obtained by optical imaging enabled by 
fluorescence labeling. To have a better understanding of delivery and clearance of the SPION-
GOx bioconjugates in animals starting from the tail vein injection, other imaging technologies 
like MRI and CT can be utilized to gain more insights. 
4.1.1 Biodistribution of Zirconium-89 labeled SPION-GOx bioconjugates using PET 
imaging 
Even though the optical imaging of solid tumors enabled by fluorescence labeling, in this case, 
with Cy5.5 and Cy7 for biodistribution is simple and sensitive, the mice had to be sacrificed in 
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order to obtain the organs of interest for an optical imaging in IVIS (In vivo imaging system). 
This is mainly because the near-infrared (NIR) light (700-100 nm wavelength) is capable of 
penetrating only several centimeters into tissue so that fluorescence signal from the internal 
organs deep inside mouse bodies was not intense enough to be detected [168]. 
An alternative approach to obtain biodistribution information is to use positron emission 
tomography (PET) to record and detect the γ-rays emitted by the injected radiopharmaceuticals 
labeled with positron-emitting radionuclide. When the radionuclide decays, a positron is ejected 
from the nucleus and soon annihilated with an electron to release two 511 keV γ rays that are 
detected by the PET scanner. The data acquired over time are collected and reconstructed into 
images showing radiotracer’s location within the organism by algorithm developed in computer. 
PET has higher sensitivity and resolution and therefore has become more popular in clinical 
diagnosis[168]. Some commonly used radiometals are Cu, Ga, Y, and Zr, since their favorable 
decay characteristics are greatly useful in coordinating with biological half-lives of different 
targeting agents like peptides, antibodies, and nanoparticles. The major advantage of the PET 
imaging over the optical imaging is that the γ-rays emitted are able to penetrate the animal body 
so that a real-time monitoring of in vivo tracer distribution could be fulfilled without sacrificing 
the mice. 
Zirconium-89 is a radioisotope of zirconium with a half-life of 78.4 hours, Eγ = 909 
keV[169]. Its long half-live makes it very useful in labeling of antibodies and nanoparticles, 
which requires slower clearing time, thus PET imaging acquisition at a longer time point. 
Furthermore, when the monoclonal antibody labeled with radionuclide internalizes, 89Zr-mAbs 
yields higher tumor-to-normal tissue ratios than the corresponding 124I-labeled mAbs[170], thus 
showing better contrast on PET images. Hydrated Zr (IV) only exists at high dilution in very 
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acidic solutions, and the total coordination number of 8 is typical in their X-ray structures[168]. 
89Zr labeling can be achieved through several chelators, but primarily through desferrioxamine B 
(DFO), which forms a stable chelate with 89Zr through 3 hydroxamate groups[171]. Actually in 
clinical PET imaging studies, all complexation of zirconium are currently performed with the 
chelator DFO[172]. When efficiently chelated with DFO, the 89Zr-DFO complex can be 
conjugated to mAbs or nanoparticles without changing the biodistribution of the mAb or 
nanoparticle thus providing important biodistribution information by PET imaging. 
Zirconium-89 is a radioisotope of zirconium with a half-life of 78.4 hours, Eγ = 909 
keV[169]. Its long half-live makes it very useful in labeling antibodies and nanoparticles, which 
requires longer clearing time. Furthermore, when the monoclonal antibody labeled with 
radionuclide internalizes, 89Zr-mAbs yields higher tumor-to-normal tissue ratios than the 
corresponding 124I-labeled mAbs[170], thus showing better contrast on PET images. Hydrated Zr 
(IV) only exists at high dilution in very acidic solutions, and the total coordination number of 8 is 
typical in their X-ray structures[168]. 89Zr labeling can be achieved through several chelators, 
but primarily through desferrioxamine B (DFO), which forms a stable chelate with 89Zr through 
3 hydroxamate groups[171]. Actually in clinical PET imaging studies, all complexation of 
zirconium are currently performed with the chelator DFO[172]. When efficiently chelated with 
DFO, the 89Zr-DFO complex can be conjugated to mAbs or nanoparticles without changing the 
biodistribution of the mAb or nanoparticles thus providing important biodistribution information 
by PET imaging. 
A few methods can be used to achieve our goal of attaching the chelator DFO to 
nanoparticles, including lysine methods, thiol methods, and click methods. A recent study by 
Perk and Vosjan et al. using Lysine methods was a great improvement from previous procedures 
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since they used a p-isothiocyanatobenzyl-bearing DFO (DFO-Bz-NCS)[173], which is a 
commercially available chelate that can form a stable thiourea linkage between chelator and 
antibody in one step. However, the lack of water insolubility in p-isothiocyanatobenzyl-DFO 
precursor requires more finesse than the straightforward N-suc-DFO chemistry[174]. Another 
concern with this lysine method is that nonspecific attachment in conjugation may hinder 
immunoreactivity if the chelate binds at an antigen-binding site. Thiol methods can do better 
because the conjugation through the thiol group of cysteine is more site specific, but no 
significant advantage in immunoreactivity was demonstrated[175]. Another method to conjugate 
mAbs or nanoparticles onto zirconium is the click chemistry as we have discussed above in 
chapter 2.1. Click chemistry is a specialized conjugation method, which expands the possibilities 
of 89Zr PET imaging application[174]. A great advantage of click chemistry method is its 
modularity, which allows spontaneous conjugations between different chelator-radiometal pairs 
or different antibodies pairs[176]. Given that the SPIONs were already functionalized with TCO 
groups, and the fact that a great amount of the TCO reacting sites were still available after the 
reaction with GOx-Tz, click chemistry between DFO-Tz and SPION-TCO was chosen as the 
radiolabeling strategy here. 
SPION-GOx bioconjugates were prepared as described above in chapter 2.2, followed by 
conjugation with 89Zr. labeled tetrazine modified DFO. Briefly, DFO-Tz was synthesized by 
adding Tz-NHS 5µmole to DFO-NH2 2µmole dissolved in 0.5ml DMF. Then 20µmole DIEA 
was subsequently added, and the reaction mixture was stirred at room temperature for 2h. Later 
the resulting mixture was left in the lyophilizer overnight to remove the solvent. The residue was 
dissolved in Acetonitrile: H2O = 1 : 1 afterwards and purified by HPLC. Electrospray ionization 
mass spectrometry (ESI-MS) was used to verify the molecular weight. Afterwards, 89Zr-labeled 
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SPION-GOx bioconjugates were prepared following the post-radiolabeling conjugation method. 
Briefly, Tz-DFO was radiolabeled with 89Zr in 1.0M HEPES (pH = 7.0) at 95°C for 30min. The 
resulting Tz-(89Zr) DFO with a specific activity of 0.5 mCi/nmole was then mixed with the 
SPION-GOx bioconjugates (0.05 mCi of Tz-(89Zr)DFO with SPION) in PBS buffer. The 
reaction mixture was incubated at 37 °C for 60 min, and the extent of labeling was determined by 
FPLC. The unconjugated Tz-(89Zr)DFO was removed by the Zeba spin desalting column to give 
89Zr-labeled SPION-GOx bioconjugates. After the successful labeling of zirconium, 89Zr labeled 
SPION-GOx and SPION were administrated to two groups of Balb/c female mice bearing 4T1 
tumors respectively using the procedures described in chapter 2.0. PET images were taken and 
analyzed for biodistribution. 
4.1.2 Preliminary Results 
ESI-MS result showed that the molecular weight of the product from DFO-NH2 and Tz-NHS 
was 787.92, which is the exact molecular weight of DFO-Tz. The radioactivity FPLC radio 
detector results from both SPION-TCO and SPION-GOx labeled with Tz-(89Zr)DFO are shown 
in Figure 31-32. The shape of the peaks for SPION and SPION-GOx from the radio FPLC is 
consistent with the ones from absorbance peaks observed from previous FPLC results without 
radiolabeling. The tiny peaks with the retention time of 33 minutes associate with unreacted 89Zr 
in the solution. We can see that ~ 98% of the 89Zr was successfully labeled on the SPION-TCO, 
while ~91% was conjugated with SPION-GOx. The shape of SPION-GOx is different from 
SPION, which also indicates that GOx was attached to form the bioconjugates from previous 
step. 
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Figure 31. FPLC of Tz-(89Zr) DFO labeled SPION-TCO. 
 
 
 
 
Figure 32. FPLC of Tz-(89Zr)DFO labeled SPION-GOx bioconjugates. 
 
The mice injected with 89Zr labeled SPION-GOx were scanned in PET 1h, 3h, and 24h 
post injection. The PET images are shown below in Figure 33-34. Biodistribution information 
was obtained 3h and 24h after the injection and shown in Figure 35-36. The results suggest that 
SPION-GOx bioconjugates are gradually accumulating in the tumor through 24h. 
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Figure 33. PET imaging of Balb/c mice bearing 4T1 tumors 1h, 3h, 24h post injection of 89Zr labeled SPION-GOx. 
 
 
 
 
Figure 34. PET imaging of tumor site. 1h, 3h, 24h post injection of 89Zr labeled SPION-GOx. 
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Figure 35. Biodistribution of 89Zr labeled SPION-GOx in major organs 3h after injection. 
 
 
 
 
Figure 36. Biodistribution of 89Zr labeled SPION-GOx in major organs 24h after injection. 
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Increase of radioactivity were observed in some organs other than the tumor, such as 
kidney, liver, bone, while there was reduction in blood, lung, spleen and pancreas. The amount 
of SPION-GOx bioconjugates in muscles, heart, and intestine remained at a constant level in the 
time period of 24 hours. All the three mice in this group were either dead or sacrificed after the 
24 h PET scanning. 
The other group of two mice were injected with 89Zr labeled SPION using the same 
procedure, but only PET scanning results were obtained, shown in Figure 37-38. The tumor area 
became brighter after 24h of injection compared to 1h, indicating the accumulation of SPION in 
the tumor over time, which is consistent with the trend of SPION-GOx bioconjugates 
accumulating in this time period. In vivo PET scanning was performed 1h and 24h after the 
injection. Limited information was obtained from this group because the exact death time of the 
two mice in this group could not be determined so that the biodistribution obtained from the 
organs would not be valid. 
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Figure 37. PET imaging of balb/c mice bearing 4T1 tumors: 1h and 24h post-injection of 89Zr labeled 
SPION. 
 
 
 
 
Figure 38. PET imaging of tumor site. 1h and 24h post injection of 89Zr labeled SPION. 
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4.1.3 Discussion 
The biodistribution results and the PET images clearly showed the accumulation of both SPION-
GOx and SPION in the tumor over a short time period of 24 hours due to the EPR effect of 
SPION. This result is very exciting because SPION-GOx bioconjugates can be efficiently 
delivered to the tumor site without any other modifications with targeting agents like peptides 
and antibodies, which suggests that this easy and convenient synthesis procedure could be 
effective. On the other hand, a targeting agent (i.e. peptide or antibody) attached to the 
bioconjugates could greatly improve the binding specificity of tumor cell, which requires further 
research in order to establish a pre-targeting 2-step cancer cell destruction system. 
Other than the tumor, increase of radioactivity was observed in some major organs, such 
as kidney, liver, bone as well. At the meantime, there was decrease in blood, lung, spleen and 
pancreas. The amount of SPION-GOx bioconjugates in muscles, heart, and intestine remained at 
a relatively constant level during the 24-hour time period. The accumulation in liver is not a 
major concern since liver has a high tolerance for toxicity. The small drop of SPION-GOx level 
in blood can be explained by a slow clearance of the large biomolecules. However, the relatively 
high amount of accumulation in the bone might be a major concern since bone marrow plays the 
key role in hematopoiesis. 
Limited biodistribution information of SPION-GOx and SPION was obtained because the 
mice in both groups were either dead before a pre-designed time point or had to be sacrificed 
after the 24 h PET scanning. Further experiments need to be designed and performed to find out 
the reasons for the inconsistency from the previous in vivo cytotoxicity evaluation. The SPION-
GOx bioconjugates did not show a very clear cytotoxicity at an even higher dosage of 12.5 
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mg/kg mouse. The mice administrated with the single dose of 12.5 mg/kg mouse appeared 
healthy one month after the injection, and no significant weight loss was observed. One of the 
possible reasons for unexpected death of mice is that the SPION-GOx suspension was not 
sanitized before the injection. The bacteria and other large size impurities that might exist in the 
suspension can be removed by simply filtering the suspension with a 0.22 µm membrane filters 
before the administration. A bacteria test as well as filtration can be conducted to verify that the 
suspension was safe for injection in the future. 
Using 89Zr to label SPION-GOx over other PET isotopes with comparable decay half-
lives such as 124I has several advantages. For example, the energy required for 89Zr production is 
lower[177]. In addition, 124I has a relatively low specificity because 124I links directly to mAbs 
via tyrosine residues, which can be subjected to dehalogenation in vivo. This may lead to 
significant radioactivity uptake in the organs that are not supposed to be targeted by the mAb-
antigen binding[178], whereas 89Zr has the higher specificity realized by the chelator DFO and 
highly specified conjugation through click chemistry. However, there is limited availability for 
89Zr. A major disadvantage of 89Zr is that the gamma emission is at a high energy level of 908.97 
keV, which may limit the radioactive dose that can be administered into patients[179]. 
Overall, PET imaging could be of great use in the future study for acquisition of 
biodistribution of any system with large biomolecules like nanoparticle or antibodies. 
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4.2 SUMMARY 
Two types of iron oxide nanoparticles, SPION and PAA-MNP have been synthesized via 
appropriate synthesis and stabilization strategies to meet the needs of desirable size and size 
distribution, proper functional groups, and great biocompatibility, etc. 
The platform using SPION-GOx bioconjugates as a novel approach for ROS-induced cell 
destruction was demonstrated to be able to effectively produce ROS from H2O2 via Fenton’s 
reaction after the oxidation of glucose catalyzed by GOx. TMB assay showed a clear blue color 
which was characterized in spectroscopy, indicating the generation of large amount of ROS. In 
vitro cell viability assay demonstrated that the SPION-GOx bioconjugates can destruct the tumor 
cells efficiently, which suggests that the platform could lead to a new cancer therapy with 
unprecedented low side effect and long-term effectiveness. The in vivo cytotoxicity evaluation 
showed that the balb/c mice can tolerate the bioconjugates with no significant weight loss at a 
dosage of 5.0 mg/kg mouse. Most importantly, SPION-GOx are able to accumulate in the tumor 
after 48 hours due to the EPR effect, and release ROS resulting in an oxidative stress that 
effectively slow down the tumor growth by targeted destruction of cancer cells. 
Additionally, MNP that are modified with the temperature responsive pNIPAM to enable 
the multistage cell separation are capable of enhancing the enrichment factor after a few 
separation cycles by improving separation efficiency caused by the non-specific interactions 
between the cells and MNP in traditional MACS system. The multiple capture-and-release cycles 
was realized by the reversible hydrophobic-hydrophilic interactions between functionalized 
MNP and target cells. Flow cytometry results suggest that A431 cells (target) could be 
effectively separated from HeLa cells (non-target) after three separation stages resulting in an 
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enrichment factor of 3.69 when the starting ratio of target to non-target is 1:2. Even though the 
separation efficiency was not dramatically enhanced, a lot of parameters in this scheme can 
potentially be tuned to optimize the system performance, like particle size, polymer density on 
particle surface, etc. 
This work suggests that Fe3O4 magnetic nanoparticles are promising material for varieties 
of biomedical applications like cancer theranostic and cell sorting for their extraordinary 
characteristics and tons of modification possibilities to meet different requirements in new 
applications. 
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